Patent Grant
8623379
The present invention is directed generally to the fields of molecular genetics and immunology. More particularly, the present invention features expression vectors and methods of administering those vectors to animals.
Vaccines have had profound and long lasting effects on world health. Smallpox has been eradicated, polio is near elimination, and diseases such as diphtheria, measles, mumps, pertussis, and tetanus are contained. Nonetheless, current vaccines address only a handful of the infections suffered by people and domesticated animals. Common infectious diseases for which there are no vaccines cost the United States alone about $120 billion dollars per year (Robinson et al., American Academy of Microbiology, May 31-Jun. 2, 1996). In first world countries, emerging infections such as immunodeficiency viruses, as well as reemerging diseases like drug resistant forms of tuberculosis, pose new threats and challenges for vaccine development. The need for both new and improved vaccines is even more pronounced in third world countries where effective vaccines are often unavailable or cost-prohibitive.
The prevalence of HIV-1 infection has made vaccine development for this recently emergent agent a high priority for world health. Pre-clinical trials on DNA vaccines have demonstrated that DNA alone can protect against highly attenuated HIV-1 challenges in chimpanzees (Boyer et al., Nature Med. 3:526-532, 1997), but not against more virulent SIV challenges in macaques (Lu et al., Vaccine 15:920-923, 1997). A combination of DNA priming plus an envelope glycoprotein boost has raised neutralizing antibody-associated protection against a homologous challenge with a non-pathogenic chimera between SIV and HIV (SHIV-IIIB) (Letvin et al., Proc. Natl. Acad. Sci. USA 94:9378-9383, 1997). A comparative trial testing eight different protocols for the ability to protect against a series of challenges with SHIVs (chimeras between simian and human immunodeficiency viruses) revealed the best containment of challenge infections by an immunization protocol that included priming by intradermal inoculation of DNA and boosting with recombinant fowl pox virus vectors (Robinson et al., Nature Med. 5:526, 1999). This containment of challenge infections was independent of the presence of neutralizing antibody to the challenge virus. Despite these and many other efforts, a vaccine for containing HIV infection is still not commercially available.
The continuing force of the AIDS epidemic illustrates the pressing need for effective vaccines against human immunodeficiency viruses (HIV), which frequently mutate and exist in several different clades (or subtypes) and recombinant forms. These subtypes and recombinant forms, which may arise either naturally or as the result of human intervention, can be distinguished by differences in the sequences of their nucleic acid. We have developed DNA and viral vectors (described at length below) that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms (unless otherwise specified, the term “clade(s)” is meant to encompass subtypes or recombinant forms of HIV). Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed).
There is also a need for an effective vaccine against poxviruses, such as the variola virus that causes smallpox; the current smallpox vaccine carries a small risk of substantial adverse side effects. Although smallpox has been eradicated, the population is still threatened by smallpox as a biological weapon. The viral vectors described herein can be used to generate an immune response against poxviruses. Thus, methods in which such vectors are administered (regardless of the precise protocol followed) can also elicit an immune response that confers protective or therapeutic effects against conditions such as smallpox (i.e., a pox viral vector can be administered before or after (e.g., 1-4 or more days after) a subject has been exposed to an agent that causes a viral disease such as smallpox). These methods can be effective regardless of whether the vectors contain vaccine inserts or what that insert encodes (e.g., proteins obtained from an HIV or proteins that elicit an immune response against one or more HIV clades).
The present invention provides plasmid vectors as well as viral vectors that can be used to deliver nucleic acids to a cell; while the invention encompasses vectors that do not contain vaccine “inserts,” when immunizing or treating a patient, the vectors will include nucleic acids that encode protein antigens that induce or enhance an immune response against a pathogen (e.g., one or more HIV clades (or subtypes or recombinant forms)). The nucleic acids or polynucleotides described herein include those having linear arrays of naturally occurring and/or synthetic nucleotides (or nucleosides) derived from cDNA (or mRNA) or genomic DNA, or derivatives thereof (the pyrimidine or purine rings can be attached to a pentose sugar, such as a ribose or deoxyribose). The sequence of the nucleic acid may or may not be identical to a sequence occurring in nature (e.g., the sequence can encode a mutant form of an HIV protein that may make the vaccine safer). Specific characteristics and specific sequences of the proteins that can be expressed by way of the vectors described herein are discussed below.
Plasmid or viral vectors can include nucleic acids representing one or more genes found in one or more HIV clades or any fragments or derivatives thereof that, when expressed, elicit an immune response against the virus (or viral clade) from which the nucleic acid was derived or obtained. The nucleic acids may be purified from HIV or they may have been previously cloned, subcloned, or synthesized and, in any event, can be the same as or different from a naturally occurring nucleic acid sequence. The plasmid vectors of the present invention may be referred to herein as, inter alia, expression vectors, expression constructs, plasmid vectors or, simply, as plasmids, regardless of whether or not they include a vaccine insert (i.e., a nucleic acid sequence that encodes an antigen or immunogen). Similar variations of the term “viral vector” may appear as well (e.g., we may refer to the “viral vector” as a “poxvirus vector,” a “vaccinia vector,” a “modified vaccinia Ankara vector,” or an “MVA vector”). The viral vector may or may not include a vaccine insert.
Accordingly, in one aspect, the invention features compositions (including pharmaceutically or physiologically acceptable compositions) that contain, but are not limited to, a vector, which may be a plasmid or viral vector, having a vaccine insert. The insert can include one or more of the sequences described herein (the features of the inserts and representative sequences are described at length below; any of these, or any combination of these, can be used as the insert). When the insert is expressed, the expressed protein(s) may generate an immune response against one or more HIV clades. One can increase the probability that the immune response will be effective against more than one clade by including sequences from more than one clade in the insert of a single vector (multi-vector vaccines are also useful and are described further below). For example, to increase the probability of generating an immune response against clade B and clade C, one can administer, to a subject, vectors that each includes an insert that encodes proteins of clade B and clade C. The subject may be a person who lives in, or travels between, parts of the world where HIV clades B and C are prevalent. Of course, expressing one or more proteins of a single clade is also beneficial and vectors that do so are within the scope of the invention (again, any inserts having the features or sequences of the exemplary inserts described herein can be used, and the inserts per se are features of the invention).
In another aspect, the invention features compositions (including pharmaceutically or physiologically acceptable compositions) that contain, but are not limited to, two vectors: a first vector that encodes one or more antigens (i.e., a vector that includes a vaccine insert) that elicit (e.g., induces or enhances) an immune response against an HIV of a first clade and a second vector that encodes one or more antigens that elicit (e.g., induces or enhances) an immune response against an HIV of a second clade. However, the compositions can contain more than first and second vectors; they can contain three, four, five, six, or more different vectors (by “different” vectors, we mean vectors that contain different regulatory elements (e.g. different promoters), or that encode different antigens or combinations of antigens, or that otherwise vary (e.g., that vary in their “backbone” sequence)). In some embodiments, the compositions can contain as many vectors as are required to elicit an immune response against two, three, four, or a majority of, if not all, HIV clades. While one vector can encode one antigen (e.g., Gag-Pol), one or more of the vectors (i.e., the first vector, the second vector, or both; the first, second, third, or all three vectors; etc.) can include nucleic acids encoding at least three antigens (e.g. Gag-Pol and Env), each of which can elicit an immune response directed primarily against the same HIV clade (i.e., the first vector can express three antigens, each of which generates a response against, primarily, clade A and a second vector can express three antigens, each of which generates a response against, primarily, clade B). In other embodiments, one or more of the vectors can elicit an immune response against more than one HIV clade (i.e., the first vector can express a first antigen (e.g., Gag-Pol) that generates a response against clade A and a second antigen (e.g., Env) that generates a response against clade B). Thus, one or more of the vectors can elicit an immune response against more than one HIV clade. Any of the types of vectors described herein, whether they are plasmid or viral vectors, or whether they individually encode antigens that elicit immune responses against primarily one, or more than one, HIV clade, can be used alone or in combination with one another, depending on the particular HIV clades to which one wishes to generate immunity.
The vaccine inserts per se (i.e., the sequences encoding HIV proteins that serve as antigens or immunogens) are also within the scope of the invention. While these inserts are described at length below, we note here that the invention features a variety of isolated nucleic acids that represent modified HIV genomes (e.g., fragments or recombinant forms of a genome or one or more HIV genes that are recombined or mutated in some way). For example, one or more nucleic acids can be deleted from one or more genes or replaced with other nucleic acids (i.e., the sequences can be fragments of a gene or genes and can contain point mutations). More specifically, the invention features isolated nucleic acids that represent HIV genomes having safety mutations (e.g., deletion of the LTRs and of sequences encoding integrase (IN), Vif, Vpr and Nef). The nucleic acids can encode Gag, PR, RT, Env, Tat, Rev, and Vpu proteins, one or more of which may contain safety mutations (particular mutations are described at length below). Moreover, the isolated nucleic acids can be of any HIV clade and nucleic acids from different clades can be used in combination (as described further below). In the work described herein, clade B inserts are designated JS (e.g., JS2, JS7, and JS7.1), clade AG inserts are designated IC (e.g., IC2, IC25, IC48, and IC90), and clade C inserts are designated IN (e.g., IN2 and IN3). These inserts are within the scope of the present invention, as are vectors (whether plasmid or viral) containing them (particular vector/insert combinations are referred to below as, for example, pGA1/JS2, pGA2/JS2 etc.
Expression vectors that carry DNA are necessarily limited in that they can only be used to immunize patients with products (i.e., proteins) encoded by DNA, and it is possible that bacterial and parasitic proteins may be atypically processed by eukaryotic cells. Another problem with existing DNA vaccines is that some vaccine insert sequences are unstable during the growth and amplification of DNA vaccine plasmids in bacteria. Instability can arise during plasmid growth where the secondary structure of the vaccine insert or of the plasmid vector (the “backbone”) can be altered by bacterial endonucleases. The expression vectors of the present invention can include a termination sequence that improves stability. The termination sequence and other regulatory components (e.g., promoters and polyadenylation sequences) are discussed at length below.
The compositions of the invention can be administered to humans, including children. Accordingly, the invention features methods of immunizing a patient (or of eliciting an immune response in a patient, which may include multi-epitope CD8+ T cell responses) by administering one or more types of vectors (e.g., one or more plasmids, which may or may not have identical sequences, components, or inserts (i.e., sequences that can encode antigens) and/or one or more viral vectors, which may or may not be identical or express identical antigens). As noted above, the vectors, whether plasmid or viral vectors, can include one or more nucleic acids obtained from or derived from (e.g., a mutant sequence is a derivative sequence) one or more HIV clades. When these sequences are expressed, they produce an antigen or antigens that elicit an immune response to one or more HIV clades. In particular embodiments, patients receive a first vector and a second vector. The first vector can encode one or more antigens of a first HIV clade (these antigens can elicit (e.g., induce or enhance) an immune response against that HIV clade) and the second vector can encode one or more antigens of a second HIV clade (here again, these antigens can elicit (e.g., induce or enhance) an immune response against the second HIV clade). In alternative embodiments, the subject can receive a third, fourth, fifth, etc. vector encoding one or more antigens from a third, fourth, fifth, etc. HIV clade (or mutants thereof). Moreover, and as in other embodiments, the antigen(s) can be from any clade (e.g., from one or more of clades A-L) or any HIV isolate.
Where the compositions contain vectors that differ either in their backbone, regulatory elements, or insert(s), the ratio of the vectors in the compositions, and the routes by which they are administered, can vary. The ratio of one type of vector to another can be equal or roughly equal (e.g., roughly 1:1 or 1:1:1, etc.). Alternatively, the ratio can be in any desired proportion (e.g., 1:2, 1:3, 1:4 . . . 1:10; 1:2:1, 1:3:1, 1:4:1 . . . 1:10:1; etc.). Thus, the invention features compositions containing a variety of vectors, the relative amounts of antigen-expressing vectors being roughly equal or in a desired proportion. While preformed mixtures may be made (and may be more convenient), one can, of course, achieve the same objective by administering two or more vector-containing compositions (on, for example, the same occasion (e.g., within minutes of one another) or nearly the same occasion (e.g., on consecutive days)).
Plasmid vectors can be administered alone (i.e., a plasmid can be administered on one or several occasions with or without an alternative type of vaccine formulation (e.g., with or without administration of protein or another type of vector, such as a viral vector)) and, optionally, with an adjuvant or in conjunction with (e.g., prior to) an alternative booster immunization (e.g., a live-vectored vaccine such as a recombinant modified vaccinia Ankara vector (MVA)) comprising an insert that may be distinct from that of the “prime” portion of the immunization or may be a related vaccine insert(s). For example, the viral vector can contain at least some of the sequence contained with the plasmid administered as the “prime” portion of the inoculation protocol (e.g., sequences encoding one or more, and possibly all, of the same antigens). The adjuvant can be a “genetic adjuvant” (i.e., a protein delivered by way of a DNA sequence). Similarly, as described further below, one can immunize a patient (or elicit an immune response, which can include multi-epitope CD8+ T cell responses) by administering a live-vectored vaccine (e.g., an MVA vector) without administering a plasmid-based (or “DNA”) vaccine. Thus, in alternative embodiments, the invention features compositions having only viral vectors (with, optionally, one or more of any of the inserts described here, or inserts having their features) and methods of administering them. The viral-based regimens (e.g., “MVA only” or “MVA-MVA” vaccine regimens) are the same as those described herein for “DNA-MVA” regimens, and the MVAs in any vaccine can be in any proportion desired. For example, in any case (whether the immunization protocol employs only plasmid-based immunogens, only viral-carried immunogens, or a combination of both), one can include an adjuvant and administer a variety of antigens, including those obtained from any HIV clade, by way of the plurality of vectors administered.
As implied by the term “immunization” (and variants thereof), the compositions of the invention can be administered to a subject who has not yet become infected with a pathogen (thus, the terms “subject” or “patient,” as used herein encompasses apparently healthy or non-HIV-infected individuals), but the invention is not so limited; the compositions described herein can also be administered to treat a subject or patient who has already been exposed to, or who is known to be infected with, a pathogen (e.g., an HIV of any clade, including those presently known as clades A-L or mutant or recombinant forms thereof).
An advantage of DNA and rMVA immunizations is that the immunogen may be presented by both MHC class I and class II molecules. Endogenously synthesized proteins readily enter processing pathways that load peptide epitopes onto MHC I as well as MHC II molecules. MHC I-presented epitopes raise CD8 cytotoxic T cell (Tc) responses, whereas MHC II-presented epitopes raise CD4 helper T cells (Th). By contrast, immunogens that are not synthesized in cells are largely restricted to the loading of MHC II epitopes and therefore raise CD4 Th but not CD8 Tc. In addition, DNA plasmids express only the immunizing antigens in transfected cells and can be used to focus the immune response on only those antigens desired for immunization. In contrast, live virus vectors express many antigens (e.g., those of the vector as well as the immunizing antigens) and prime immune responses against both the vector and the immunogen. Thus, we believed these vectors could be highly effective at boosting a DNA-primed response by virtue of the large amounts of antigen that can be expressed by a live vector preferentially boosting the highly targeted DNA-primed immune response. The live virus vectors also stimulate the production of pro-inflammatory cytokines that augment immune responses. Thus, administering one or more of the DNA vectors described herein (as a “prime”) and subsequently administering one or more of the viral vectors (as a “boost”), could be more effective than DNA-alone or live vectors-alone at raising both cellular and humoral immunity. Insofar as these vaccines may be administered by DNA expression vectors and/or recombinant viruses, there is a need for plasmids that are stable in bacterial hosts and safe in animals. Plasmid-based vaccines that may have this added stability are disclosed herein, together with methods for administering them to animals, including humans.
The antigens encoded by DNA or rMVA are necessarily proteinaceous. The terms “protein,” “polypeptide,” and “peptide” are generally interchangeable, although the term “peptide” is commonly used to refer to a short sequence of amino acid residues or a fragment of a larger protein. In any event, serial arrays of amino acid residues, linked through peptide bonds, can be obtained by using recombinant techniques to express DNA (e.g., as was done for the vaccine inserts described and exemplified herein), purified from a natural source, or synthesized.
Other advantages of DNA-based vaccines (and of viral vectors, such as pox virus-based vectors) are described below. The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
a and 2b relate to pGA1.
a and 3b relate to pGA1.1.
a and 4b relate to pGA1.2.
a and 6b relate to pGA2.
a and 7b relate to pGA2.1.
a and 8b relate to pGA2.2.
a-10c relate to pGA2/JS2.
a-11c relate to pGA2/JS7.
a-12c relate to pGA2/JS7.1.
a-13c relate to pGA1/IC25.
a-14c relate to pGA1/IC2.
a-15c relate to pGA1/IC48.
a-16c relate to pGA1/IC90.
a-17c relate to pGA1/IN3.
a-18c relate to pGA1/IN2.
This invention encompasses a wide variety of vectors and types of vectors (e.g., plasmid and viral vectors), each of which can, but do not necessarily, include one or more nucleic acid sequences that encode one or more antigens that elicit (e.g., that induce or enhance) an immune response against the pathogen from which the antigen was obtained or derived (the sequences encoding proteins that elicit an immune response may be referred to herein as “vaccine inserts” or, simply, “inserts”; when a mutation is introduced into a naturally occurring sequence, the resulting mutant is “derived” from the naturally occurring sequence). We point out that the vectors do not necessarily encode antigens to make it clear that vectors without “inserts” are within the scope of the invention and that the inserts per se are also compositions of the invention.
Accordingly, the invention features the nucleic acid sequences disclosed herein, analogs thereof, and compositions containing those nucleic acids (whether vector plus insert or insert only; e.g., physiologically acceptable solutions, which may include carriers such as liposomes, calcium, particles (e.g., gold beads) or other reagents used to deliver DNA to cells). The analogs can be sequences that are not identical to those disclosed herein, but that include the same or similar mutations (e.g., the same point mutation or a similar point mutation) at positions analogous to those included in the present sequences (e.g., any of the JS, IC, or IN sequences disclosed herein). A given residue or domain can be identified in various HIV clades even though it does not appear at precisely the same numerical position. The analogs can also be sequences that include mutations that, while distinct from those described herein, similarly inactivate an HIV gene product. For example, a gene that is truncated to a greater or lesser extent than one of the genes described here, but that is similarly inactivated (e.g., that loses a particular enzymatic activity) is within the scope of the present invention.
The pathogens and antigens, which are described in more detail below, include human immunodeficiency viruses of any clade (e.g. from any known clade or from any isolate (e.g., clade A, AG, B, C, D, E, F, G, H, I, J, K, or L)). When the vectors include sequences from a pathogen, they can be administered to a patient to elicit an immune response. Thus, methods of administering antigen-encoding vectors, alone or in combination with one another, are also described herein. These methods can be carried out to either immunize patients (thereby reducing the patient's risk of becoming infected) or to treat patients who have already become infected; when expressed, the antigens may elicit both cell-mediated and humoral immune responses that may substantially prevent the infection (e.g., immunization can protect against subsequent challenge by the pathogen) or limit the extent of its impact on the patient's health. While in many instances the patient will be a human patient, the invention is not so limited. Other animals, including non-human primates, domesticated animals and livestock can also be treated.
The compositions described herein, regardless of the pathogen or pathogenic subtype (e.g., the HIV clade(s)) they are directed against, can include a nucleic acid vector (e.g., a plasmid). As noted herein, vectors having one or more of the features or characteristics (particularly the oriented termination sequence and a strong promoter) of the plasmids designated pGA1, pGA2 (including, of course, those vectors per se), can be used as the basis for a vaccine or therapy. Such vectors can be engineered using standard recombinant techniques (several of which are illustrated in the examples, below) to include sequences that encode antigens that, when administered to, and subsequently expressed in, a patient will elicit (e.g., induce or enhance) an immune response that provides the patient with some form of protection against the pathogen from which the antigens were obtained or derived (e.g., protection against infection, protection against disease, or amelioration of one or more of the signs or symptoms of a disease). The encoded antigens can be of any HIV clade or subtype or any recombinant form thereof. With respect to inserts from immunodeficiency viruses, different isolates exhibit clustal diversity, with each isolate having overall similar diversity from the consensus sequence for the clade (see, e.g., Subbarao et al., AIDS 10(Suppl A):S13-23, 1996). Thus, any isolate can be used as a reasonable representative of sequences for other isolates of the same clade. Accordingly, the compositions of the invention can be made with, and the methods described herein can be practiced with, natural variants of genes or nucleic acid molecules that result from recombination events, alternative splicing, or mutations (these variants may be referred to herein simply as “recombinant forms” of HIV).
Moreover, one or more of the inserts within any construct can be mutated to decrease their natural biological activity (and thereby increase their safety) in humans (these human-made variants may also be referred to herein as “recombinant forms” of HIV (there are naturally occurring recombinant forms as well)). As noted above in the description of JS2, JS7 and JS7.1 and as described below (see, e.g., Examples 7-10), mutations can be introduced into sequences that participate in encapsidation. For example, one can mutate (by, for example, deletion of all or a part of) a cis-acting RNA encapsidation sequence in the non-coding regulatory sequence of an HIV (e.g., HIV-1). Alternatively, or in addition, one can mutate sequences that encode any antigenic proteins (e.g., any HIV antigen, including those listed above (e.g., the viral RT or protease).
For example, the compositions of the invention include those having two vectors: (a) a first vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against a human immunodeficiency virus (HIV) of a first subtype or recombinant form and (b) a second vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against an HIV of a second subtype or recombinant form. The compositions can be pharmaceutically acceptable and may include a carrier or adjuvant (discussed further below). Moreover, the insert of the first vector or the insert of the second vector can include the sequences of two or more of: (a) a gag, pol, env, tat, rev, nef, vif, vpr, or vpu gene or (b) mutants thereof and, optionally, (c) non-coding regulatory sequences (including the sequences of single promoters) of the HIV genome. At least one of the two or more sequences can be mutant or mutated so as to limit the encapsidation of viral RNA (preferably, the mutation(s) limit encapsidation appreciably).
One can introduce mutations and determine their effect (on, for example, expression or immunogenicity) using techniques known in the art; antigens that remain well expressed (e.g., antigens that are expressed about as well as or better than their wild type counterparts), but are less biologically active than their wild type counterparts, are within the scope of the invention. Techniques are also available for assessing the immune response. One can, for example, detect anti-viral antibodies or virus-specific T cells.
The mutant constructs (e.g., a vaccine insert) can include sequences encoding one or more of the substitution mutants described herein (see, e.g. the Examples) or an analogous mutation in another HIV clade. In addition to, or alternatively, HIV antigens can be rendered less active by deleting part of the gene sequences that encode them. Thus, the compositions of the invention can include constructs that encode antigens that, while capable of eliciting an immune response, are mutant (whether encoding a protein of a different length or content than a corresponding wild type sequence) and thereby less able to carry out their normal biological function when expressed in a patient. As noted above, expression, immunogenicity, and activity can be assessed using standard techniques for molecular biology and immunology.
Several plasmids have been constructed and used to express antigens (e.g., the pGA2/JS2 construct has gone through immunogenicity studies in macaques). The plasmids made and used include pGA1 and its derivatives pGA1.1 and pGA1.2; and pGA2, and its derivatives pGA2.1 and pGA2.2 (see Examples 1-8). The vaccine constructs we made are typically referred to with the “backbone” vector and the “insert” being separated by a backslash. These constructs express HIV-1 antigens, and those constructs can be administered to patients as described herein. While antigens (wild type and those containing mutations that render them safer for administration) are discussed at length below, we note here that, based upon our present evidence, plasmids containing JS7-like inserts appear to exhibit better immunogenicity and are more efficient in priming an immune response (as evidenced by anti-Env antibodies) than are plasmids containing JS2-like inserts. pGA2/JS7 and pGA2/JS7.1 differ from pGA2/JS2 in several ways, one of which is the source of their respective antigens. In pGA2/JS7 and pGA2/JS7.1, the Gag and Pol genes were obtained from HIV-1 HXB2, whereas in pGA2/JS2 those genes were obtained from a closely related isolate of HIV-1, HIV-1 BH10. Accordingly, the invention features inserts (as well as vectors and compositions containing them) that include Gag and Pol genes obtained from HIV-1 HXB2. Moreover, these inserts can contain mutations that inhibit one or more of the biological activities carried out by Gag-Pol. The vaccine inserts designated JS7 and JS2 also differ in that JS7 has an inactivating point mutation in its protease gene. This mutation facilitates the formation of viral like particles (VLPs) by, we believe, precluding premature intracellular cleavage of the pr55 Gag protein. pGA2/JS7 and pGA2/JS7.1 both contain this protease mutation and both constructs produce VLPs in abundance. Accordingly, the invention features inserts that include mutant gag and/or pol sequences (e.g., mutations (e.g., one or more deletions or point mutations) that inhibit the protease gene). Additional point mutations in the vpu gene in pGA2/JS7.1 resulted in a loss of Vpu expression and an increase in Env expression (in pGA2/JS7.1, the start site of Vpu is mutated along with a downstream ATG to eliminate translation of Vpu). The increase in Env expression does not compromise Gag expression.
Identical or analogous changes can be made in any vaccine insert that includes gag, pol; any vaccine insert that encodes a viral protease; or any vaccine insert that includes a vpu gene (regardless of the clade or isolate from which it was obtained). Moreover, these changes can be made in vaccine inserts that are placed in any of the plasmid or live-vectored vaccines (e.g., MVA) described herein (i.e., in any plasmid having one or more of the features or characteristics of the pGA vectors, the pGA vectors themselves, or the vaccinia vectors that may be used alone or in conjunction with (e.g., to boost) a DNA-primed patient).
Any plasmid within the scope of the invention can be tested for expression by transfecting cells, such as 293T cells (a human embryonic kidney cell line) and assessing the level of antigen expression (by, for example, an antigen-capture ELISA or a Western blot). Plasmids that express immunogens at a level comparable to, or higher than, the plasmids tested herein are strong therapeutic candidates and are within the scope of the invention (of course, any construct that elicits an effective immune response (e.g., any desirable degree of protection from infection or other therapeutic benefit) is within the scope of the invention, regardless of the level of antigen expression it generates). One can similarly assess the ability of candidate vectors to produce VLPs; the more the vectors' products resemble VLPs, the more likely they are to elicit a strong antibody response (while this is a desirable feature, vectors that fail to form VLPs are nevertheless useful and are within the scope of the present invention). In addition to assessing expression and VLP formation in cell culture, one can assess candidate vectors in vivo. For example, one can assess immunogenicity in animal models (and, eventually, in human patients). Plasmids that have substantially the same sequence as the pGA vectors described herein and that express one or more of the antigens described herein are within the scope of the invention so long as they are immunogenic enough to induce or enhance a therapeutically beneficial response in a patient (a plasmid can have substantially the same sequence as a pGA vector even if one or more of the component parts of the plasmid, such as the marker gene or antibiotic-resistance gene, has been deleted). In tests in animals for immunogenicity, one can perform an intracellular cytokine assay or an ELISPOT assay for IFN-γ production in response to stimulation with an antigenic peptide to evaluate the frequency of responding T cells to that peptide. Proliferation assays can also be carried out. Antigens produced by transient transfection can be used for stimulation, and supernatants from mock-transfected cultures can serve as controls. If desired, the data can be presented as a stimulation index (the growth of cultures in the presence of pathogenic (e.g., viral) antigens divided by the growth of cultures in the presence of mock antigen).
The nucleic acid vectors of the invention, including pGA1 and pGA2 and their derivatives can encode at least one antigen (which may also be referred to as an immunogen) obtained from, or derived from, any HIV clade or isolate (i.e., any subtype or recombinant form of HIV). The antigen (or immunogen) may be: a structural component of an HIV virus; glycosylated, myristoylated, or phosphorylated; one that is expressed intracellularly, on the cell surface, or secreted (antigens that are not normally secreted may be linked to a signal sequence that directs secretion). More specifically, the antigen can be all, or an antigenic portion of, Gag, gp120, Pol, Env (e.g., a CCR5-using Env; see, for example,
Particular inserts and insert-bearing compositions include the following. Where the composition includes either a vector with an insert or an insert alone, and that insert encodes a single antigen, the antigen can be a wild type or mutant gag sequence (e.g., a gag sequence having a mutation in one or more of the sequences encoding a zinc finger (e.g., a mutation at a nucleotide at any of positions 1279-1281, 1288-1290, 1342-1344, or 1351-1353 of SEQ ID NOs:7 or 8 or at an analogous position in an HIV gag sequence of another clade). As the mutation is intended to alter the encoded protein, it will not be a silent mutation (e.g., one at the third-base wobble position of a codon (this is true in the context of gag or any other HIV sequence included in an insert of the invention). A mutation at one or more of the positions just listed would change one or more of the cysteine residues at positions 392, 395, 413, or 416 to another residue (e.g., serine). Alternatively, the mutation can be at any of positions 1271-1273, 1280-1282, 1334-1336, or 1343-1345 of any of SEQ ID NOs:10-13) or at an analogous position in an HIV gag sequence of another clade. Such a mutation would change one or more of the cysteine residues at positions 390, 393, 411, or 414 to another residue (e.g., serine). Alternatively, the mutation can be at any of positions 1260-1262, 1269-1271, 1323-1325, or 1332-1334 of SEQ ID NOs:14 or 15 or at an analogous position in an HIV gag sequence of another clade. Such a mutation would change one or more of the cysteine residues at positions 390, 393, 411, or 414 to another residue (e.g., serine).
Where the composition includes either a vector with an insert or an insert alone, and that insert encodes multiple protein antigens, one of the antigens can be a wild type or mutant gag sequence, including those described above. Similarly, where a composition includes more than one type of vector or more than one type of insert, at least one of the vectors or inserts (whether encoding a single antigen or multiple antigens) can include a wild type or mutant gag sequence, including those described above or analogous sequences from other HIV clades. For example, where the composition includes first and second vectors, the vaccine insert in either or both vectors (whether the insert encodes single or multiple antigens) can encode Gag; where both vectors encode Gag, the Gag sequence in the first vector can be from one HIV clade (e.g., clade B) and that in the second vector can be from another HIV clade (e.g., clade C).
Where the composition includes either a vector with an insert or an insert alone, and that insert encodes a single antigen, the antigen can be wild type or mutant Pol. The sequence can be mutated by deleting or replacing one or more nucleic acids, and those deletions or substitutions can result in a Pol gene product that has less enzymatic activity than its wild type counterpart (e.g., less integrase activity, less reverse transcriptase (RT) activity, or less protease activity). For example, one can inhibit RT by introducing a mutation at one or more of positions 2454-2456 or 2697-2699 of SEQ ID NO:7 or at an analogous position in a sequence of another subtype or recombinant form. While the invention is not limited to mutations that have any particular effect on enzyme activity, we believe the mutation at position 2454-2456 inhibits RT by inactivating the polymerase's active site and that the mutation at position 2697-2699 inhibits RT by ablating strand transfer activity. Accordingly, these mutations and others that have similar effects on the activity of the gene product are within the scope of the invention. More specifically, the mutation can change the amino acid encoded by the nucleotides at 2454-2456 of SEQ ID NO:7 (aspartic acid (D)) to any another amino acid (e.g., asparagine (N)). Alternatively, or in addition, one can inhibit the polymerase's RNase H activity by, for example, introducing a mutation at nucleotides 3333-3335 of SEQ ID NO:7 (e.g., a mutation that changes the glutamic acid residue (E) to tryptophan (W)). Alternatively, the mutation can be at any of positions 2418-2420, 2661-2663, or 3297-3299 of SEQ ID NOs:8 or 9 (other clade B inserts). Alternatively, the mutation can be at any of positions 2410-2412, 2653-2655, or 3289-3291 of any of SEQ ID NOs:10-13 (for example, the aspartic acid (D), tryptophan (W) and glutamic acid (E) residues at those positions can be changed to asparagine (N), threonine (T), and/or glutamine (Q), respectively). Alternatively, the mutation can be at any of positions 2387-2389, 2630-2632, or 3266-3268 of SEQ ID NOs:14 or 15. Nucleic acids encoding analogous residues in other clades can be identified by one of ordinary skill in the art, even if those residues are not found at precisely the same position as they were in the clades tested here.
Where the composition includes either a vector with an insert or an insert alone, and that insert encodes multiple protein antigens, one of the antigens can be a wild type or mutant pol sequence, including those described above (these multi-protein-encoding inserts can also encode the wild type or mutant gag sequences described above). Similarly, where a composition includes more than one type of vector or more than one type of insert, at least one of the vectors or inserts (whether encoding a single antigen or multiple antigens) can include a wild type or mutantpol sequence, including those described above (and, optionally, a wild type or mutant gag sequence, including those described above (i.e., the inserts can encode Gag-Pol)). For example, where the composition includes first and second vectors, the vaccine insert in either or both vectors (whether the insert encodes single or multiple antigens) can encode Pol; where both vectors encode Pol, the Pol sequence in the first vector can be from one HIV clade (e.g., clade B) and that in the second vector can be from another HIV clade (e.g., clade AG).
Where an insert includes some or all of the pol sequence, another portion of the pol sequence that can be altered is the sequence encoding the protease activity (regardless of whether or not sequences affecting other enzymatic activities of Pol have been altered). For example, one can introduce a mutation at position 1641-1643 of SEQ ID NO:8 (e.g., a mutation that changes the glutamic acid residue normally encoded by this codon to another amino acid residue, such as alanine (A)). As with the other mutants (e.g., gag mutants) described herein, analogous mutations can be made in sequences obtained from other HIV clades. For example, one can introduce a mutation at position 1633-1635 of SEQ ID NO:10 (changing arginine (R) to another amino acid, such as asparagine (N)), at position 1703-1705 of SEQ ID NO:12 (changing glycine (G) to another residue, such as valine (V)), or at position 1828-1830 of SEQ ID NO:13 (changing leucine (L) to another residue, such as methionine (M) (SEQ ID NOs:10, 12, and 13 all represent clade AG sequences). In an insert from clade C, one can introduce a mutation at position 1610-1612 of SEQ ID NO:14 (changing aspartic acid (D) to another amino acid residue, such as asparagine (N)).
Where the composition includes either a vector with an insert or an insert alone, and that insert encodes a single antigen, the antigen can be a wild type or mutant Env, Tat, Rev, Nef, Vif, Vpr, or Vpu. Where the composition includes either a vector with an insert or an insert alone, and that insert encodes multiple protein antigens, one of the antigens can be a wild type or mutant Env. For example, multi-protein expressing inserts can encode wild type or mutant Gag-Pol and Env; they can also encode wild type or mutant Gag-Pol and Env and one or more of Tat, Rev, Nef, Vif, Vpr, or Vpu (each of which can be wild type or mutant). As with other antigens, Env, Tat, Rev, Nef, Vif, Vpr, or Vpu can be mutant by virtue of a deletion, addition, or substitution of one or more amino acid residues (e.g., any of these antigens can include a point mutation). With respect to Env, one or more mutations can be in any of the domains shown in
More specifically, the compositions of the invention can include a vector (e.g., a plasmid or viral vector) that encodes: (a) a Gag protein in which one or more of the zinc fingers has been inactivated to limit the packaging of viral RNA; (b) a Pol protein in which (i) the integrase activity has been inhibited by deletion of some or all of the pol sequence and (ii) the polymerase, strand transfer and/or RNase H activity of reverse transcriptase has been inhibited by one or more point mutations within the pol sequence; and (c) Env, Tat, Rev, and Vpu, with or without mutations. In this embodiment, as in others, the encoded proteins can be obtained or derived from a subtype A, B or C HIV (e.g., HIV-1) or recombinant forms thereof. Where the compositions include non-identical vectors, the sequence in each type of vector can be from a different HIV clade (or subtype or recombinant form thereof). For example, the invention features compositions that include plasmid vectors encoding the antigens just described (Gag-Pol, Env etc.), where some of the plasmids include antigens that are obtained from, or derived from, one clade and other plasmids include antigens that are obtained (or derived) from another clade. Mixtures representing two, three, four, five, six, or more clades (including all clades) are within the scope of the invention.
Where first and second vectors are included in a composition, either vector can be pGA1/JS2, pGA1/JS7, pGA1/JS7.1, pGA2/JS2, pGA2/JS7, pGA2/JS7.1 (pGA1.1 can be used in place of pGA1 and pGA2.1 or pGA2.2 can by used in place of pGA2). Similarly, either vector can be pGA1/IC25, pGA1/IC2, pGA1/IC48, pGA1/IC90, pGA2/IC25, pGA2/IC2, pGA2/IC48, or pGA2/IC90 (here again, pGA1.1 or pGA1.2 can be used in place of pGA1 and pGA2.1 or pGA2.2 can be used in place of pGA2). In alternative embodiments, the encoded proteins can be those of, or those derived from, a subtype C HIV (e.g., HIV-1) or a recombinant form thereof. For example, the vector can be pGA1/IN2, pGA1.1/IN2, pGA1.2/IN2, pGA1/IN3, pGA1.1/IN3, pGA1.2/IN3, pGA2/IN2, pGA2.1 pGA2.2/IN2, pGA2/IN3, pGA2.1/IN3, or pGA2.2/IN3.
The encoded proteins can also be those of, or those derived from, any of HIV clades (or subtypes) E, F, G, H, I, J, K or L or recombinant forms thereof. An HIV-1 classification system has been published by Los Alamos National Laboratory (HIV Sequence Compendium-2001, Kuiken et al, published by Theoretical Biology and Biophysics Group T-10, Los Alamos, N.M., (2001); http://hiv-web.lanl.gov).
The compositions of the invention can also include a vector (e.g., a plasmid vector) encoding: (a) a Gag protein in which one or both zinc fingers have been inactivated; (b) a Pol protein in which (i) the integrase activity has been inhibited by deletion of some or all of the pol sequence, (ii) the polymerase, strand transfer and/or RNase H activity of reverse transcriptase has been inhibited by one or more point mutations within the pol sequence and (iii) the proteolytic activity of the protease has been inhibited by one or more point mutations; and (c) Env, Tat, Rev, and Vpu, with or without mutations. As noted above, proteolytic activity can be inhibited by introducing a mutation at positions 1641-1643 of SEQ ID NO:8 or at an analogous position in the sequence of another HIV clade. For example, the plasmids can contain the inserts described herein as JS7, IC25, and IN3. As is true for plasmids encoding other antigens, plasmids encoding the antigens just described can be combined with (e.g., mixed with) other plasmids that encode antigens obtained from, or derived from, a different HIV clade (or subtype or recombinant form thereof). The inserts per se (sans vector) are also within the scope of the invention.
Other vectors of the invention include plasmids encoding a Gag protein (e.g., a Gag protein in which one or both of the zinc fingers have been inactivated); a Pol protein (e.g., a Pol protein in which integrase, RT, and/or protease activities have been inhibited; a Vpu protein (which may be encoded by a sequence having a mutant start codon); and Env, Tat, and/or Rev proteins (in a wild type or mutant form). As is true for plasmids encoding other antigens, plasmids encoding the antigens just described can be combined with (e.g., mixed with) other plasmids that encode antigens obtained from, or derived from, a different HIV clade (or subtype or recombinant form thereof). The inserts per se (sans vector) are also within the scope of the invention.
The plasmids described above, including those that express the JS2 or JS7 series of clade B HIV-1 sequences, can be administered to any subject, but may be most beneficially administered to subjects who have been, or who are likely to be, exposed to an HIV of clade B (the same is true for vectors other than plasmid vectors). Similarly, plasmids or other vectors that express an IN series of clade C HIV-1 sequences can be administered to a subject who has been, or who may be, exposed to an HIV of clade C. As vectors expressing antigens of various clades can be combined to elicit an immune response against more than one clade (this can be achieved whether one vector expresses multiple antigens from different clades or multiple vectors express single antigens from different clades), one can tailor the vaccine formulation to best protect a given subject. For example, if a subject is likely to be exposed to regions of the world where clades other than clade B predominate, one can formulate and administer a vector or vectors that express an antigen (or antigens) that will optimize the elicitation of an immune response to the predominant clade or clades.
The antigens they express are not the only parts of the plasmid vectors that can vary. Useful plasmids may or may not contain a terminator sequence that substantially inhibits transcription (the process by which RNA molecules are formed upon DNA templates by complementary base pairing). Useful terminator sequences include the lambda T0 terminator and functional fragments or variants thereof The terminator sequence is positioned within the vector in the same orientation and at the C terminus of any open reading frame that is expressed in prokaryotes (i.e., the terminator sequence and the open reading frame are operably linked). By preventing read through from the selectable marker into the vaccine insert as the plasmid replicates in prokaryotic cells, the terminator stabilizes the insert as the bacteria grow and the plasmid replicates.
Selectable marker genes are known in the art and include, for example, genes encoding proteins that confer antibiotic resistance on a cell in which the marker is expressed (e.g., resistance to kanamycin, ampicillin, or penicillin). The selectable marker is so-named because it allows one to select cells by virtue of their survival under conditions that, absent the marker, would destroy them. The selectable marker, the terminator sequence, or both (or parts of each or both) can be, but need not be, excised from the plasmid before it is administered to a patient. Similarly, plasmid vectors can be administered in a circular form, after being linearized by digestion with a restriction endonuclease, or after some of the vector “backbone” has been altered or deleted.
The nucleic acid vectors can also include an origin of replication (e.g., a prokaryotic ori) and a transcription cassette that, in addition to containing one or more restriction endonuclease sites, into which an antigen-encoding insert can be cloned, optionally includes a promoter sequence and a polyadenylation signal. Promoters known as strong promoters can be used and may be preferred. One such promoter is the cytomegalovirus (CMV) intermediate early promoter, although other (including weaker) promoters may be used without departing from the scope of the present invention. Similarly, strong polyadenylation signals may be selected (e.g., the signal derived from a bovine growth hormone (BGH) encoding gene, or a rabbit β globin polyadenylation signal (Bohm et al., J. Immunol. Methods 193:29-40, 1996; Chapman et al., Nucl. Acids Res. 19:3979-3986, 1991; Hartikka et al., Hum. Gene Therapy 7:1205-1217, 1996; Manthorpe et al., Hum. Gene Therapy 4:419-431, 1993; Montgomery et al., DNA Cell Biol. 12:777-783, 1993)).
The vectors can further include a leader sequence (a leader sequence that is a synthetic homolog of the tissue plasminogen activator gene leader sequence (tPA) is optional in the transcription cassette) and/or an intron sequence such as a cytomegalovirus (CMV) intron A or an SV40 intron. The presence of intron A increases the expression of many antigens from RNA viruses, bacteria, and parasites, presumably by providing the expressed RNA with sequences that support processing and function as a eukaryotic mRNA. Expression can also be enhanced by other methods known in the art including, but not limited to, optimizing the codon usage of prokaryotic mRNAs for eukaryotic cells (Andre et al., J. Virol. 72:1497-1503, 1998; Uchijima et al., J. Immunol. 161:5594-5599, 1998). Multi-cistronic vectors may be used to express more than one immunogen or an immunogen and an immunostimulatory protein (Iwasaki et al., J. Immunol. 158:4591-4601, 1997a; Wild et al., Vaccine 16:353-360, 1998). Thus (and as is true with other optional components of the vector constructs), vectors encoding one or more antigens from one or more HIV clades or isolates may, but do not necessarily, include a leader sequence and an intron (e.g., the CMV intron A).
The vectors of the present invention differ in the sites that can be used for accepting antigen-encoding sequences and in whether the transcription cassette includes intron A sequences in the CMVIE promoter. Accordingly, one of ordinary skill in the art may modify the insertion site(s) or cloning site(s) within the plasmid without departing from the scope of the invention. Both intron A and the tPA leader sequence have been shown in certain instances to enhance antigen expression (Chapman et al., Nucleic Acids Research 19:3979-3986, 1991).
As described further below, the vectors of the present invention can be administered with an adjuvant, including a genetic adjuvant. Accordingly, the nucleic acid vectors, regardless of the antigen they express, can optionally include such genetic adjuvants as GM-CSF, IL-15, IL-2, interferon response factors, secreted forms of flt-3, and mutated caspase genes. Genetic adjuvants can also be supplied in the form of fusion proteins, for example by fusing one or more C3d gene sequences (e.g., 1-3 (or more) C3d gene sequences) to an expressed antigen.
In the event the vector administered is a pGA vector, it can comprise the sequence of, for example, pGA1 (SEQ ID NO:1) or derivatives thereof (e.g., SEQ ID NOs:2 and 3) or pGA2 (SEQ ID NO:4) or derivatives thereof (e.g., SEQ ID NOs:5 and 6). The pGA vectors are described in more detail here (see also Examples 1-8). pGA1 is a 3897 bp plasmid that includes a promoter (bp 1-690), the CMV-intron A (bp 691-1638), a synthetic mimic of the tPA leader sequence (bp 1659-1721), the bovine growth hormone polyadenylation sequence (bp 1761-1983), the lambda T0 terminator (bp 1984-2018), the kanamycin resistance gene (bp 2037-2830) and the ColEI replicator (bp 2831-3890). The DNA sequence of the pGA1 construct (SEQ ID NO:1) is shown in
pGA2 is a 2947 bp plasmid lacking the 947 bp of intron A sequences found in pGA1. pGA2 is the same as pGA1, except for the deletion of intron A sequences. pGA2 is valuable for cloning sequences which do not require an upstream intron for efficient expression, or for cloning sequences in which an upstream intron might interfere with the pattern of splicing needed for good expression.
pGA plasmids having “backbone” sequences that differ from those disclosed herein are also within the scope of the invention so long as the plasmids retain substantially all of the characteristics necessary to be therapeutically effective (e.g., one can substitute nucleotides, add nucleotides, or delete nucleotides so long as the plasmid, when administered to a patient, induces or enhances an immune response against a given or desired pathogen). For example, 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, or more than 100 nucleotides can be deleted or replaced.
In one embodiment, the methods of the invention (e.g., methods of eliciting an immune response in a patient) can be carried out by administering to the patient a therapeutically effective amount of a physiologically acceptable composition that includes a vector, which can contain a vaccine insert that encodes one or more antigens that elicit an immune response against an HIV. The vector can be a plasmid vector having one or more of the characteristics of the pGA constructs described above (e.g., a selectable marker gene, a prokaryotic origin of replication, a termination sequence (e.g., the lambda T0 terminator) and operably linked to the selectable gene marker, and a eukaryotic transcription cassette comprising a promoter sequence, a nucleic acid insert encoding at least one antigen derived from an immunodeficiency virus, and a polyadenylation signal sequence). Of course, the vaccine inserts of the invention may be delivered by plasmid vectors that do not have the characteristics of the pGA constructs (e.g., vectors other than pGA1 or pGA2). Alternatively, the composition can include any viral or bacterial vector that includes an insert described herein. The invention, therefore, encompasses administration of a single type of vector (i.e., plasmid or viral vectors that contain the same vaccine insert (i.e., an insert encoding the same antigens)). As is made clear elsewhere, the patient may receive two types of vectors, and each of those vectors can elicit an immune response against an HIV of a different clade. For example, the invention features methods in which a patient receives a composition that includes (a) a first vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against a human immunodeficiency virus (HIV) of a first subtype or recombinant form and (b) a second vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against an HIV of a second subtype or recombinant form. The first and second vectors can be any of those described herein. Similarly, the inserts in the first and second vectors can be any of those described herein.
A therapeutically effective amount of a vector (whether considered the first, second, third, etc. vector) can be administered by an intramuscular or an intradermal route, together with a physiologically acceptable carrier, diluent, or excipient, and, optionally, an adjuvant. A therapeutically effective amount of the same or a different vector can subsequently be administered by an intramuscular or an intradermal route, together with a physiologically acceptable carrier, diluent, or excipient, and, optionally, an adjuvant to boost an immune response. Such components can be readily selected by one of ordinary skill in the art, regardless of the precise nature of the antigens incorporated in the vaccine or the vector by which they are delivered.
The methods of eliciting an immune response can be carried out by administering only the plasmid vectors of the invention, by administering only the viral vectors of the invention, or by administering both (e.g., one can administer a plasmid vector (or a mixture or combination of plasmid vectors)) to “prime” the immune response and a viral vector (or a mixture or combination of viral vectors)) to “boost” the immune response. Where plasmid and viral vectors are administered, their inserts may be “matched.” To be “matched,” one or more of the sequences of the inserts (e.g., the sequences encoding Gag, or the sequences encoding Env, etc.) within the plasmid and viral vectors may be identical, but the term is not so limited. “Matched” sequences can also differ from one another. For example, inserts expressed by viral vectors are “matched” to those expressed by DNA vectors when the sequences used in the DNA vector are mutated or further mutated to allow (or optimize) replication of a viral vector that encodes those sequences and expression of the encoded antigens (e.g., Gag, Gag-Pol, or Env) in cells infected with the viral vector.
At least some of the immunodeficiency virus vaccine inserts of the present invention were designed to generate non-infectious VLPs (a term that can encompass true VLPs as well as aggregates of viral proteins) from a single DNA. This was achieved using the subgenomic splicing elements normally used by immunodeficiency viruses to express multiple gene products from a single viral RNA. The subgenomic splicing patterns are influenced by (i) splice sites and acceptors present in full length viral RNA, (ii) the Rev responsive element (RRE) and (iii) the Rev protein. The splice sites in retroviral RNAs use the canonical sequences for splice sites in eukaryotic RNAs. The RRE is an approximately 200 bp RNA structure that interacts with the Rev protein to allow transport of viral RNAs from the nucleus to the cytoplasm. In the absence of Rev, the approximately 10 kb RNA of immunodeficiency virus mostly undergoes splicing to the mRNAs for the regulatory genes Tat, Rev, and Nef. These genes are encoded by exons present between RT and Env and at the 3′ end of the genome. In the presence of Rev, the singly spliced mRNA for Env and the unspliced mRNA for Gag and Pol are expressed in addition to the multiply spliced mRNAs for Tat, Rev, and Nef.
The expression of non-infectious VLPs from a single DNA affords a number of advantages to an immunodeficiency virus vaccine. The expression of a number of proteins from a single DNA affords the vaccinated host the opportunity to respond to the breadth of T- and B-cell epitopes encompassed in these proteins. The expression of proteins containing multiple epitopes allows epitope presentation by diverse histocompatibility types. By using whole proteins, one offers hosts of different histocompatibility types the opportunity to raise broad-based T cell responses. This may be essential for the effective containment of immunodeficiency virus infections, whose high mutation rate supports ready escape from immune responses (Evans et al., Nat. Med. 5:1270-1276, 1999; Poignard et al., Immunity 10:431-438, 1999, Evans et al., 1995). In the context of the present vaccination scheme, just as in drug therapy, multi-epitope T cell responses that require multiple mutations for escape will provide better protection than single epitope T cell responses (which require only a single mutation for escape).
Immunogens can also be engineered to be more or less effective for raising antibody or Tc by targeting the expressed antigen to specific cellular compartments. For example, antibody responses are raised more effectively by antigens that are displayed on the plasma membrane of cells, or secreted therefrom, than by antigens that are localized to the interior of cells (Boyle et al., Int. Immunol. 9:1897-1906, 1997; Inchauspe et al., DNA Cell. Biol. 16:185-195, 1997). Tc responses may be enhanced by using N-terminal ubiquitination signals which target the DNA-encoded protein to the proteosome causing rapid cytoplasmic degradation and more efficient peptide loading into the MHC I pathway (Rodriguez et al., J. Virol. 71:8497-8503, 1997; Tobery et al., J. Exp. Med. 185:909-920, 1997; Wu et al., J. Immunol. 159:6037-6043, 1997). For a review on the mechanistic basis for DNA-raised immune responses, refer to Robinson and Pertmer, Advances in Virus Research, vol. 53, Academic Press (2000).
Another approach to manipulating immune responses is to fuse immunogens to immunotargeting or immunostimulatory molecules. To date, the most successful of these fusions have targeted secreted immunogens to antigen presenting cells (APCs) or lymph nodes (Boyle et al., Nature 392:408-411, 1998). Accordingly, the invention features the HIV antigens described herein fused to immunotargeting or immunostimulatory molecules such as CTLA-4, L-selectin, or a cytokine (e.g., an interleukin such as IL-1, IL-2, IL-4, IL-7, IL-10, IL-15, or IL-21). Nucleic acids encoding such fusions and compositions containing them (e.g., vectors and physiologically acceptable preparations) are also within the scope of the present invention.
DNA can be delivered in a variety of ways, any of which can be used to deliver the plasmids of the present invention to a subject. For example, DNA can be injected in, for example, saline (e.g., using a hypodermic needle) or delivered biolistically (by, for example, a gene gun that accelerates DNA-coated beads). Saline injections deliver DNA into extracellular spaces, whereas gene gun deliveries bombard DNA directly into cells. The saline injections require much larger amounts of DNA (typically 100-1000 times more) than the gene gun (Fynan et al., Proc. Natl. Acad. Sci. USA 90:11478-11482, 1993). These two types of delivery also differ in that saline injections bias responses towards type 1 T-cell help, whereas gene gun deliveries bias responses towards type 2 T-cell help (Feltquate et al., J. Immunol. 158:2278-2284, 1997; Pertmer et al., J. Virol. 70:6119-6125, 1996). DNAs injected in saline rapidly spread throughout the body. DNAs delivered by the gun are more localized at the target site. Following either method of inoculation, extracellular plasmid DNA has a short half life of about 10 minutes (Kawabata et al., Pharm. Res. 12:825-830, 1995; Lew et al., Hum. Gene Ther. 6:553, 1995). Vaccination by saline injections can be intramuscular (i.m.) or intradermal (i.d.); gene gun deliveries can be administered to the skin or to surgically exposed tissue such as muscle.
While other routes of delivery are generally less favored, they can nevertheless be used to administer the compositions of the invention. For example, the DNA can be applied to the mucosa or by a parenteral route of inoculation. Intranasal administration of DNA in saline has met with both good (Asakura et al, Scand. J. Immunol. 46:326-330, 1997; Sasaki et al., Infect. Immun. 66:823-826, 1998b) and limited (Fynan et al., Proc. Natl. Acad. Sci. USA 90:11478-82, 1993) success. The gene gun has successfully raised IgG following the delivery of DNA to the vaginal mucosa (Livingston et al., Ann. New York Acad. Sci. 772:265-267, 1995). Some success at delivering DNA to mucosal surfaces has also been achieved using liposomes (McCluskie et al., Antisense Nucleic Acid Drug Dev. 8:401-414, 1998), microspheres (Chen et al., J. Virol. 72:5757-5761, 1998a; Jones et al., Vaccine 15:814-817, 1997) and recombinant Shigella vectors (Sizemore et al., Science 270:299-302, 1995; Sizemore et al., Vaccine 15:804-807, 1997). Agents such as these (liposomes, microspheres and recombinant Shigella vectors) can be used to deliver the nucleic acids of the present invention.
The dose of DNA needed to raise a response depends upon the method of delivery, the host, the vector, and the encoded antigen. The method of delivery may be the most influential parameter. From 10 μg to 5 mg of DNA is generally used for saline injections of DNA, whereas from 0.2 μg to 20 μg of DNA is used more typically for gene gun deliveries of DNA. In general, lower doses of DNA are used in mice (10-100 μg for saline injections and 0.2 μg to 2 μg for gene gun deliveries), and higher doses in primates (100 μg to 1 mg for saline injections and 2 μg to 20 μg for gene gun deliveries). The much lower amount of DNA required for gene gun deliveries reflect the gold beads directly delivering DNA into cells.
In addition to the DNA vectors described above, a number of different poxviruses can be used either alone (i.e., without a nucleic acid or DNA prime) or as the boost component of a vaccine regimen. MVA has been particularly effective in mouse models (Schneider et al., Nat. Med. 4:397-402, 1998). MVA is a highly attenuated strain of vaccinia virus that was developed toward the end of the campaign for the eradication of smallpox, and it has been safety tested in more than 100,000 people (Mahnel et al., Berl. Munch Tierarztl Wochenschr 107:253-256, 1994; Mayr et al. Zentralbl. Bakteriol. 167:375-390, 1978). During over 500 passages in chicken cells, MVA lost about 10% of its genome and the ability to replicate efficiently in primate cells. Despite its limited replication, MVA has proved to be a highly effective expression vector (Sutter et al., Proc. Natl. Acad. Sci. USA 89:10847-10851, 1992), raising protective immune responses in primates for parainfluenza virus (Durbin et al. J. Infect. Dis. 179:1345-1351, 1999), measles (Stittelaar et al. J. Virol. 74:4236-4243, 2000), and immunodeficiency viruses (Barouch et al., J. Virol. 75:5151-5158, 2001; Ourmanov et al., J. Virol. 74:2740-2751, 2000; Amara et al., J. Virol. 76:7625-7631, 2002). The relatively high immunogenicity of MVA has been attributed in part to the loss of several viral anti-immune defense genes (Blanchard et al., J. Gen. Virol. 79:1159-1167, 1998).
Vaccinia viruses have been used to engineer viral vectors for recombinant gene expression and as recombinant live vaccines (Mackett et al., Proc. Natl. Acad. Sci. USA 79:7415-7419; Smith et al., Biotech. Genet. Engin. Rev. 2:383-407, 1984). DNA sequences, which may encode any of the HIV antigens described herein, can be introduced into the genomes of vaccinia viruses. If the gene is integrated at a site in the viral DNA that is non-essential for the life cycle of the virus, it is possible for the newly produced recombinant vaccinia virus to be infectious (i.e., able to infect foreign cells) and to express the integrated DNA sequences. Preferably, the viral vectors featured in the compositions and methods of the present invention are highly attenuated. Several attenuated strains of vaccinia virus were developed to avoid undesired side effects of smallpox vaccination. The modified vaccinia Ankara (MVA) virus was generated by long-term serial passages of the Ankara strain of vaccinia virus on chicken embryo fibroblasts (CVA; see Mayr et al., Infection 3:6-14, 1975). The MVA virus is publicly available from the American Type Culture Collection (ATCC; No. VR-1508; Manassas, Va.). The desirable properties of the MVA strain have been demonstrated in clinical trials (Mayr et al., Zentralbl Bakteriol. 167:375-390, 1978; Stickl et al., Dtsch. Med. Wschr. 99:2386-2392, 1974; see also, Sutter and Moss, Proc. Natl. Acad. Sci. USA 89:10847-10851, 1992). During these studies in over 120,000 humans, including high-risk patients, no side effects were associated with the use of MVA vaccine.
The MVA vectors can be prepared as follows. A DNA construct that contains a DNA sequence that encodes a foreign polypeptide (e.g., any of the HIV antigens described herein) and that is flanked by MVA DNA sequences adjacent to a naturally occurring deletion with the MVA genome (e.g., deletion III or other non-essential site(s); six major deletions of genomic DNA (designated deletions I, II, III, IV, V, and VI) totaling 31,000 base pairs have been identified (Meyer et al., J. Gen. Virol. 72:1031-1038, 1991)) is introduced into cells infected with MVA under conditions that permit homologous recombination to occur. Once the DNA construct has been introduced into the eukaryotic cell and the foreign DNA has recombined with the viral DNA, the recombinant vaccinia virus can be isolated by methods known in the art (isolation can be facilitated by use of a detectable marker). The DNA constructed to be inserted can be linear or circular (e.g., a plasmid, linearized plasmid, gene, gene fragment, or modified HIV genome). The foreign DNA sequence is inserted between the sequences flanking the naturally occurring deletion. For better expression of a DNA sequence, the sequence can include regulatory sequences (e.g., a promoter, such as the promoter of the vaccinia 11 kDa gene or the 7.5 kDa gene). The DNA construct can be introduced into MVA-infected cells by a variety of methods, including calcium phosphate-assisted transfection (Graham et al., Virol. 52:456-467, 1973 and Wigler et al., Cell 16:777-785, 1979), electroporation (Neumann et al., EMBO J. 1:841-845, 1982) microinjection (Graessmann et al., Meth. Enzymol. 101:482-492, 1983), by means of liposomes (Straubinger et al., Meth. Enzymol. 101:512-527, 1983), by means of spheroplasts (Schaffner, Proc. Natl. Acad. Sci. USA 77:2163-2167, 1980), or by other methods known in the art.
One can arrive at an appropriate dosage when delivering DNA by way of a viral vector, just as one can when a plasmid vector is used. For example, one can deliver 1×108 pfu of an MVA-based vaccine, and administration can be carried out intramuscularly, intradermally, intravenously, or mucosally.
Accordingly, the invention features a composition comprising: (a) a first viral vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against a human immunodeficiency virus (HIV) of a first subtype or recombinant form and (b) a second viral vector comprising a vaccine insert encoding one or more antigens that elicit an immune response against an HIV of a second subtype or recombinant form. The viral vector can be a recombinant poxvirus or a modified vaccinia Ankara (MVA) virus, and the insert can be any of the HIV antigens described herein from any clade (e.g., one can administer a prophylactically or therapeutically effective amount of an MVA that encodes a clade A, B, or C HIV (e.g., HIV-1 antigen). Moreover, when administered in conjunction with a plasmid vector (e.g., when administered subsequent to a “DNA prime”), the MVA-borne sequence can be “matched” to the plasmid-borne sequence. For example, a vaccinia virus (e.g., MVA) that expresses a recombinant clade B sequence can be matched to the JS series of plasmid inserts. Similarly, a vaccinia virus (e.g., MVA) that expresses a recombinant clade A sequence can be matched to the IC series of plasmid inserts; a vaccinia virus (e.g., MVA) that expresses a recombinant clade C sequence can be matched to the IN series of plasmid inserts. While particular clades are exemplified below, the invention is not so limited. The compositions that contain a viral vector, can include viral vectors that express an HIV antigen from any known clade (including clades A, B, C, D, E, F, G, H, I, J, K or L). Methods of eliciting an immune response can, of course, be carried out with compositions expressing antigens from any of these clades as well.
Either the plasmid or viral vectors described here can be administered with an adjuvant (i.e., any substance that is added to a vaccine to increase the vaccine's immunogenicity) and they can be administered by any conventional route of administration (e.g., intramuscular, intradermal, intravenous or mucosally; see below). The adjuvant used in connection with the vectors described here (whether DNA or viral-based) can be one that slowly releases antigen (e.g., the adjuvant can be a liposome), or it can be an adjuvant that is strongly immunogenic in its own right (these adjuvants are believed to function synergistically). Accordingly, the vaccine compositions described here can include known adjuvants or other substances that promote DNA uptake, recruit immune system cells to the site of the inoculation, or facilitate the immune activation of responding lymphoid cells. These adjuvants or substances include oil and water emulsions, Corynebacterium parvum, Bacillus Calmette Guerin, aluminum hydroxide, glucan, dextran sulfate, iron oxide, sodium alginate, Bacto-Adjuvant, certain synthetic polymers such as poly amino acids and co-polymers of amino acids, saponin, REGRESSIN (Vetrepharm, Athens, Ga.), AVRIDINE (N,N-dioctadecyl-N′,N′-bis(2-hydroxyethyl)-propanediamine), paraffin oil, and muramyl dipeptide. Genetic adjuvants, which encode immunomodulatory molecules on the same or a co-inoculated vector, can also be used. For example, GM-CSF, IL-15, IL-2, interferon response factors, and mutated caspase genes can be included on a vector that encodes a pathogenic immunogen (such as an HIV antigen) or on a separate vector that is administered at or around the same time as the immunogen is administered. Expressed antigens can also be fused to an adjuvant sequence such as one, two, three or more copies of C3d.
The compositions described herein can be administered in a variety of ways including through any parenteral or topical route. For example, an individual can be inoculated by intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular methods. Inoculation can be, for example, with a hypodermic needle, needleless delivery devices such as those that propel a stream of liquid into the target site, or with the use of a gene gun that bombards DNA on gold beads into the target site. The vector comprising the pathogen vaccine insert can be administered to a mucosal surface by a variety of methods including intranasal administration, i.e., nose drops or inhalants, or intrarectal or intravaginal administration by solutions, gels, foams, or suppositories. Alternatively, the vector comprising the vaccine insert can be orally administered in the form of a tablet, capsule, chewable tablet, syrup, emulsion, or the like. In an alternate embodiment, vectors can be administered transdermally, by passive skin patches, iontophoretic means, and the like.
Any physiologically acceptable medium can be used to introduce a vector (whether nucleic acid-based or live-vectored) comprising a vaccine insert into a patient. For example, suitable pharmaceutically acceptable carriers known in the art include, but are not limited to, sterile water, saline, glucose, dextrose, or buffered solutions. The media may include auxiliary agents such as diluents, stabilizers (i.e., sugars (glucose and dextrose were noted previously) and amino acids), preservatives, wetting agents, emulsifying agents, pH buffering agents, additives that enhance viscosity or syringability, colors, and the like. Preferably, the medium or carrier will not produce adverse effects, or will only produce adverse effects that are far outweighed by the benefit conveyed.
The present invention is further illustrated by the following examples, which are provided by way of illustration and should not be construed as limiting. The contents of all references, published patent applications and patents cited throughout the present application are hereby incorporated by reference in their entirety. A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.
pGA1 (see
The lambda T0 terminator (Scholtissek et al., Nucleic Acids Res. 15:3185, 1987) prevents read through from the kanamycin resistance gene into the eukaryotic expression cassette (in this case the vaccine transcription cassette) during prokaryotic growth of the plasmid. By preventing read through into the vaccine expression cassette, the terminator helps stabilize plasmid inserts during growth in bacteria.
The ColE1 replicator, the kanamycin resistance gene, and the transcriptional control elements for eukaryotic cells were combined in one plasmid using PCR fragments from the commercial vector pZErO-2.1 (Invitrogen, Carlsbad, Calif.) and a eukaryotic expression vector pJW4303 (Lu et al., Vaccine 15:920-923, 1997).
An 1859 bp fragment from pZErO-2.1 (nucleotides 1319 to 3178) included the ColE1 origin of replication and the kanamycin resistance gene. A 2040 bp fragment from pJW4303 (nucleotides 376 to 2416) included the CMVIE promoter with intron A, a synthetic homolog of the tissue plasminogen activator leader (tPA), and the bovine growth hormone polyadenylation site (BGHpA). Fragments were amplified by polymerase chain reaction (PCR) with oligonucleotide primers containing Sal I sites. A ligation product with the transcription cassettes for kanamycin resistance from pZErO2 and the eukaryotic transcription cassette form pJW4303 in opposite transcriptional orientations, was identified for further development. Nucleotide numbering for this parent of the pGA vectors was started from the first bp of the 5′ end of the CMV promoter.
The T0 terminator was introduced into this parent for the pGA vectors by PCR amplification of a 391 bp fragment with a BamH I restriction endonuclease site at its 5′ end and an Xba I restriction endonuclease site at its 3′ end. The initial 355 bp of the fragment were sequences in the BGHpA sequence derived from the pJW4303 transcription cassette, the next 36 bases in a synthetic oligonucleotide introduced the T0 sequence and the Xba I site. The introduced T0 terminator sequences comprised the sequence: 5′-ATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAA-3′ (SEQ ID NO: 16).
The T0 terminator containing the BamH I-Xba I fragment was substituted for the homologous fragment without the T0 terminator in the plasmid created from pZErO-2 and pJW4303. The product was sequenced to verify the T0 orientation (
A region in the eukaryotic transcription cassette between nucleotides 1755-1845 contained the last 30 bp of the reading frame for SIV nef. This region was removed from pGA by mutating the sequence at nt 1858 and generating an Avr II restriction endonuclease site. A naturally occurring Avr II site is located at nt 1755. Digestion with Avr II enzyme and then religation with T4 DNA ligase allowed for removal of the SIV segment of DNA between nucleotides 1755-1845. To facilitate cloning of HIV-1 sequences into pGA vectors, a Cla I site was introduced at bp 1648 and an Rsr II site at bp 1747 using standard techniques for site directed mutagenesis. Constructions were verified by sequence analyses.
pGA1.1 (SEQ ID NO: 2) is identical to pGA1 except that the multiple cloning site has been altered to include an EcoRI site. This was accomplished by site directed mutagenesis using the following primers: 5′-GCTGCTGCTGTGTGGAGAATTCTTCGTTTCGGC-3′ (forward) and 5′-GCCGAAACGAAGAATTCTCCACACAGCAGCAGC-3′ (reverse) (SEQ ID NOs:17 and 18 respectively). Accordingly, the pGA1.1 vector is an embodiment of the invention; as are other vectors having one or more of the features or characteristics of a pGA plasmid (see the detailed description), but different restriction endonuclease sites in the multi-cloning site (e.g., the invention encompasses plasmids that are otherwise substantially similar to pGA1 but that have more, less, or different restriction endonuclease sites in their multi-cloning site).
pGA1.2 (SEQ ID NO: 3) is identical to pGA1.1 except that the multiple cloning site has been altered to include BamHI and XhoI sites 5′ to the EcoRI site. This was accomplished by site directed mutagenesis using the primer 5′-CTGCAGTCACCATGGATCCTTGCACT-CGAGGATGCAATGAAGAG-3′ (SEQ ID NO:19) and the reverse primer
pGA2 is schematically illustrated in
PGA2.1 (SEQ ID NO:5) is identical to pGA2 except that the multiple cloning site has been altered to include an EcoRI sites. This was accomplished by site directed mutagenesis using the following primers: forward 5′-GCTGCTGCTGTGTGGAGAATTCTTCGTTTCGGC-3′ (SEQ ID NO:17) and reverse 5′-GCCGAAACGAAGAATTCTCCACACAGCAGCAGC-3′ (SEQ ID NO:18). Accordingly, the pGA2.1 vector is an embodiment of the invention; as are other vectors having one or more of the features or characteristics of a pGA plasmid (see the detailed description), but different restriction endonuclease sites in the multi-cloning site (e.g., the invention encompasses plasmids that are otherwise substantially similar to pGA1 but that have more, less, or different restriction endonuclease sites in their multi-cloning site).
PGA2.2 (SEQ ID NO: 6) is identical to pGA1.1 except that the multiple cloning site has been altered to include a BamHI and a XhoI site 5′ to the EcoRI site. This was accomplished by site directed mutagenesis using the forward primer 5′-GAACTCATTCTATGGATCCTTGC-TCGAGTGGATGCAATGAAGAG-3′ and the reverse primer 5′-CTCTTCATTGCATC-CACTCGAGCAAGGATCCATAGAATGAGTTC-3′ (SEQ ID NOs:23 and 24 respectively)
HIV-1 vaccine inserts for the pGA1 and pGA2 series of vectors were constructed to express multiple HIV-1 proteins from a single RNA transcript using the same subgenomic splicing mechanisms used by immunodeficiency viruses. To ensure that these multiprotein-expressing vectors did not form infectious virus, deletions and point mutations were introduced to cripple essential steps in the retrovirus life cycle.
The HIV-1 vaccine inserts described below can be expressed in any of the pGA vectors or further derivatives of these vectors. The examples for inserts that are given below are given with the example of the pGA vector that is planned for future use of that insert. However, any of these inserts can be used in any of the pGA vectors as well as other eukaryotic expression vectors.
The sequence of pGA2/JS2 is shown in
To achieve a multiprotein-expressing clade B vaccine insert with high expression, candidate vaccines were constructed from seven different HIV-1 sequences, as shown in Table 1.
An initial construct, pBH10-VLP, was prepared from IIIB sequences that are stable in bacteria and have high expression in eukaryotic cells. The HIV-1-BH10 sequences were obtained from the NIH-sponsored AIDS Repository (catalog #90). The parental pHIV-1-BH10 was used as the template for PCR reactions to construct pBH10-VLP.
Primers were designed to yield a Gag-Rt PCR product (5′ PCR product) encompassing (from 5′ to 3′) 105 bp of the 5′ untranslated leader sequence and sequences from the start codon for Gag to the end of the RT coding sequence. The oligonucleotide primers introduced a Cla I site at the 5′ end of the PCR product and EcoR I and Nhe I sites at the 3′ end of the PCR product. Sense primer (5′-GAGCTCTATCGATGCAGGACTCGGCTTGC-3′ (SEQ ID NO:25 and antisense primer (5′-GGCAGGTTTTAATCGCTAGCCTATGCTCTCC-3′ (SEQ ID NO:26) were used to amplify the 5′ PCR product.
The PCR product for the env region of HIV-1 (3′ PCR product) encompassed the vpu, tat, rev, and env sequences and the splice acceptor sites necessary for proper processing and expression of their respective mRNAs. An EcoR I site was introduced at the 5′ end of this product and Nhe I and Rsr II sites were introduced into the 3′ end. Sense primer (5′-GGGCAGGAGTGCTAGCC-3′ (SEQ ID NO:27) and antisense primer 5′-CCACACTACTTTCGGACCGCTAGCCACCC-3′ (SEQ ID NO: 28)) were used to amplify the 3′ PCR product. The 5′ PCR product was cloned into pGA1 at the Cla I and Nhe I sites of pGA1 and the identity of the construct confirmed by sequencing. The 3′ PCR product was then inserted into the 5′ clone at the EcoR I and Nhe I sites to yield pBH10. The construction of this plasmid resulted in proviral sequences that lacked LTRs, integrase, vif. vpr and nef sequences (see
Because pBH10-VLP encoded a CXCR-4 using Env, rather than a CCR-5 using Env, sequences encoding six different R5 Envs were substituted for env sequence in the pBH10 intermediate (Table 1). EcoR I to BamH I fragments encompassing tat, rev, vpu and env coding sequences from different viral genomes were substituted into pBH10. The resulting env and rev sequences were chimeras for the substituted sequences and HIV-1-BH10 sequences (see
Next, inactivating point mutations were introduced into JS1 to further increase the safety of this construct for use in humans as a non-infectious vaccine agent (of course, mutations can be made preemptively, before any testing at all) (see
The mutations were made using a site directed mutagenesis kit (Stratagene) following the manufacturer's protocol. All mutations were confirmed by sequencing. Primer pairs used for the mutagenesis were:
The sequence of pGA2/JS7 is shown in
The forward primer introduced a Cla I site at the same position as that found in the JS2 insert and the reverse primer introduced a unique EcoR I site analogous to the same site in the JS2 insert. This PCR fragment was then inserted into pGA1.1 for mutagenesis. The safety mutations in the zinc finger regions and the RT mutations were then introduced as previously described for the JS2 insert. JS7 also differs from JS2 in having an inactivating codon mutation at the active site of protease. This mutation was introduced using the
Once the mutations were confirmed by sequencing, the HXB-2 Gag-Pol insert was introduced into pGA2/JS2 via the Cla I and EcoR I sites. In contrast to the JS2 insert that expresses aggregates of HIV-1 proteins due to premature cleavage of the pr55Gag polyprotein by the viral protease, the JS7 insert forms immature virus like particles (VLPs) that bud from the plasma membrane of DNA-expressing cells.
The sequence of pGA2/JS7.1 is shown in
The sequence of pGA1/IC25 is shown in
To achieve a multiprotein-expressing clade AG vaccine insert with high expression, candidate vaccines were constructed from four different AG HIV-1 isolates, as shown in Table 2.
For each isolate, the forward primer 5′-AAGATCTATCGATGCAAGGACTCGGCTTGC-3′ (SEQ ID NO:45) and the reverse primer 5′-TTCCAATTGCTGTGAGAATTCTCA-TGCTCTTCTTGGG-3′ (SEQ ID NO:46) were used to amplify the 5′ Gag-RT PCR product. The 3′ PCR product for the Env region encompassed the vpu, tat, rev, and env sequences and the splice acceptor sites necessary for proper processing and expression of their respective mRNAs. An EcoR I site was introduced at the 5′ end of this product and Nhe I and Rsr II sites were introduced into the 3′ end. A forward primer 5′-AAGGGGTTAAAGCTATAATAAG-AATTCTGCA-3′ (SEQ ID NO:47) and a reverse primer 5′-CCTTTGCTGCCCTATCTGA-TTCTTCTAGG-3′ (SEQ ID NO:48) were used to amplify the 3′ PCR product. Of these, those from patient 928 proved particularly favorable for further development (Table 2. The 928 sequences with deletions but not codon mutations were designated IC1.
The strategy used to construct IC25, a more disabled virus than IC1, was similar to that used to construct JS7 from JS1. Specifically four codon mutations were introduced into gag sequences to inactivate the zinc fingers that are involved in RNA packaging, three codon mutations were introduced into pol sequences to inactivate transcription, strand transfer and RNaseH activities of reverse transcriptase and the codon at the active site of the protease was mutated to limit proteolytic cleavage of viral Gag proteins and the maturation of viral particles. The protease mutations also limited premature cleavage of the Gag polyprotein and allowed budding of immature VLPs.
The inactivating codon mutations were made using a site directed mutagenesis kit (Stratagene) following the manufacturer's protocol. All mutations were confirmed by sequencing. Primer pairs used for the mutagenesis were:
The sequence of pGA1/IC2 is shown in
The sequence of pGA1/IC48 is shown in
The sequence of pGA1/IC90 is shown in
The sequence of pGA1/IN3 is shown in
To achieve a multiprotein-expressing clade C vaccine insert with high expression, candidate vaccines were constructed from four different clade C HIV-1 sequences that were obtained from the US NIAID AIDS repository, as shown in Table 3. Of these, those from the Indian clone proved particularly favorable for further development.
5′ and 3′ sequences from the Indian clone were cloned into pGA1.2 using oligonucleotides and PCR to generate 5′ and 3′ fragments. The 5′ fragment encoding Gag and RT was generated using the forward primer 5′-CGCAGGATCCGGCTTGCTGAAG-3′ (SEQ ID NO:65), which incorporated a BamH I site at the 5′ end of the fragment, and the reverse primer 5′-TCTACTCGAGCTTATTATAGCACTCTCCTG-3′ (SEQ ID NO:66), which incorporated an Xho I site as well as two stop codons at the 3′ end of the fragment. The 3′ fragment encoding Tat, Rev, Vpu, and Env was generated using the forward primer 5′-CCTCTCGAGATACTTGGACAGGAG-3′ (SEQ ID NO:67) and the reverse primer 5′-CACTTGCTAGCCATTTTACTGCAAAGC-3′ (SEQ ID NO:68). These were designed such that Xho I and Nhe I restriction sites were incorporated at the 5′ and 3′ ends, respectively of the 3′ fragment. These fragments were introduced into pGA1.2 using directed cloning to create pGA1.2/IN1.
The strategy used to construct IN3, a more disabled virus than IN1, was similar to that used to construct JS7 from JS1. Specifically four codon mutations were introduced into gag sequences to inactivate the zinc fingers that are involved in RNA packaging, three codon mutations were introduced into pol sequences to inactivate transcription, strand transfer and RNaseH activities of reverse transcriptase and the codon at the active site of the protease was mutated to limit proteolytic cleavage of viral Gag proteins and the maturation of viral particles. The protease mutations also limited premature cleavage of the Gag polyprotein and allowed budding of immature VLPs.
The inactivating codon mutations were made using a site directed mutagenesis kit (Stratagene) following the manufacturer's protocol. All mutations were confirmed by sequencing. Primer pairs used for the mutagenesis were:
The sequence of pGA1/IN2 is shown in
Sequences for the JS, IC, and IN inserts were used to prepare matched recombinant modified vaccinia Ankara (rMVA) vectors. These matched vectors can be used as booster inoculations for the various DNAs. They can also be used for both priming and boosting an anti-HIV immune response. The sequences provided to generate the viral vector included the three inactivating point mutations in reverse transcriptase. A representative study, in which a recombinant MVA vector was constructed and characterized, follows.
MVA virus (which may be obtained from the American Type Culture Collection) was plaque purified three times by terminal dilutions in chicken embryo fibroblasts (CEF), which were made from 9-day old SPF Premium SPAFAS fertile chicken eggs, distributed by B and E eggs (Stevens, Pa.). Secondary CEF cells were infected at an MOI of 0.05 of MVA and transfected with 2 pLW-48 (as described above; see
Aliquots of MVA/HIV48 infected cell lysates were analyzed by radio-immunoprecipitation and immunostaining with monoclonal antibodies for expression of both the Env and Gag-Pol protein. In both of these tests, each of these proteins was detected. The recombinant virus was shown to produce gag particles in the supernatant of infected cells by pelleting the 35S-labeled particles on a 20% sucrose cushion. By electron microscopy, gag particles were visualized both outside and budding from cells as well as within vacuoles of cells. The gag particles had envelope protein on their surface.
Thus, we made a recombinant MVA virus that expressed the ADA truncated envelope and the HXB2 Gag-Pol protein. The MVA recombinant virus is made using a transiently expressed GUS marker that is deleted in the final virus. High expression of the ADA envelope is possible because of a new hybrid early/late promoter (Psyn II; see, e.g.,
This application is a continuation-in-part of U.S. Ser. No. 10/093,953 (pending), which was filed on Mar. 8, 2002, and which is a continuation-in-part of U.S. Ser. No. 09/798,675 (which is pending and was published Aug. 8, 2002, under publication number 20020106798), which was filed on Mar. 2, 2001, and which claims the benefit under 35 U.S.C. §119(e) of the filing dates of four provisional applications (U.S. Ser. No. 60/251,083, filed Dec. 1, 2000, U.S. Ser. No. 60/186,364, filed Mar. 2, 2000, U.S. Ser. No. 60/324,845, filed Sep. 25, 2001, and U.S. Ser. No. 60/325,004, filed Sep. 26, 2001). U.S. Ser. No. 10/093,953 is also a continuation-in-part of International Application No. PCT/US01/06795, which was filed on Mar. 2, 2001, and was published in English under International Publication No. WO01/92470 on Dec. 6, 2001. The contents of all applications listed above are hereby incorporated by reference in their entirety. The instant application is also a continuation-in-part of International Application No. PCT/US02/06713, which was filed on Mar. 1, 2002, and was published in English under International Publication No. WO 02/072754 on Sep. 19, 2002, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application U.S. Ser. No. 60/274,434, filed Mar. 8, 2001.
The work described herein was supported, at least in part, by grants from the National Institutes of Health (P01 AI43045, P01 AI49364, and R21 AI44325). The United States Government may therefore have certain rights in this invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5169763 | Kieny et al. | Dec 1992 | A |
| 5185146 | Altenburger | Feb 1993 | A |
| 5256767 | Salk et al. | Oct 1993 | A |
| 5445953 | Dorner et al. | Aug 1995 | A |
| 5494807 | Paoletti et al. | Feb 1996 | A |
| 5589466 | Felgner et al. | Dec 1996 | A |
| 5593972 | Weiner et al. | Jan 1997 | A |
| 5614404 | Mazzara et al. | Mar 1997 | A |
| 5676950 | Small et al. | Oct 1997 | A |
| 5736368 | Mazzara et al. | Apr 1998 | A |
| 5741492 | Hurwitz et al. | Apr 1998 | A |
| 5747324 | Mazzara et al. | May 1998 | A |
| 5747338 | Giese et al. | May 1998 | A |
| 5756103 | Paoletti et al. | May 1998 | A |
| 5766599 | Paoletti et al. | Jun 1998 | A |
| 5795577 | Kieny et al. | Aug 1998 | A |
| 5817637 | Weiner et al. | Oct 1998 | A |
| 5846946 | Huebner et al. | Dec 1998 | A |
| 5849304 | Moss et al. | Dec 1998 | A |
| 5853725 | Salk et al. | Dec 1998 | A |
| 5858775 | Johnson | Jan 1999 | A |
| 5863542 | Paoletti et al. | Jan 1999 | A |
| 5879925 | Rovinski et al. | Mar 1999 | A |
| 5911989 | Katinger et al. | Jun 1999 | A |
| 5928930 | Salk et al. | Jul 1999 | A |
| 5985641 | Haynes et al. | Nov 1999 | A |
| 6051410 | Mazzara et al. | Apr 2000 | A |
| 6077662 | Compans et al. | Jun 2000 | A |
| 6080408 | Rovinski et al. | Jun 2000 | A |
| 6086891 | Hurwitz et al. | Jul 2000 | A |
| 6099847 | Tobin et al. | Aug 2000 | A |
| 6103244 | Dorner et al. | Aug 2000 | A |
| 6121021 | Rovinski et al. | Sep 2000 | A |
| 6140114 | Klatzmann et al. | Oct 2000 | A |
| 6156952 | Bryant et al. | Dec 2000 | A |
| 6171596 | Earl et al. | Jan 2001 | B1 |
| 6204250 | Bot et al. | Mar 2001 | B1 |
| 6214804 | Felgner et al. | Apr 2001 | B1 |
| 6221633 | Ertl et al. | Apr 2001 | B1 |
| 6265183 | Dorner et al. | Jul 2001 | B1 |
| 6291157 | Rovinski et al. | Sep 2001 | B1 |
| 6306625 | Jacobs et al. | Oct 2001 | B1 |
| 6448083 | Larocca et al. | Sep 2002 | B1 |
| 6544527 | Rovinski et al. | Apr 2003 | B1 |
| 6554527 | O'Donnell et al. | Apr 2003 | B1 |
| 6663871 | McMichael et al. | Dec 2003 | B1 |
| 6841381 | Robinson et al. | Jan 2005 | B1 |
| Number | Date | Country |
|---|---|---|
| 0 335 635 | Oct 1989 | EP |
| 0 538 496 | Aug 1991 | EP |
| WO 8909620 | Oct 1989 | WO |
| WO 8912095 | Dec 1989 | WO |
| WO 9107425 | May 1991 | WO |
| WO 9727311 | Jul 1997 | WO |
| WO 9856919 | Dec 1998 | WO |
| WO 9963098 | Dec 1999 | WO |
| WO 0000216 | Jan 2000 | WO |
| WO 0102607 | Jan 2001 | WO |
| WO 0147955 | Jul 2001 | WO |
| WO 0152886 | Jul 2001 | WO |
| WO 0182962 | Nov 2001 | WO |
| WO 0192470 | Dec 2001 | WO |
| WO02072754 | Sep 2002 | WO |
| WO 03004657 | Jan 2003 | WO |
| WO03004657 | Jan 2003 | WO |
| WO 03072754 | Sep 2003 | WO |
| Entry |
|---|
| Cheonis N. Status Report on HIV Vaccine Development [online]. San Francisco AIDS Foundation, Winter 2000 [retrieved on Mar. 27, 2006], Retrieved from the Internet: <http://www.thebody.com/sfaf/winter00/vaccine.html#>. |
| Ho, M. AIDS Vaccines Trials Dangerous [online]. ISIS News, No. 11/12, Oct. 2001 [retrieved on Mar. 27, 2006]. Retrieved from the internet: <http://www.i-sis.org.uk/isisnews/i-sisnews11-19.php>. |
| Tonini et al. Current approaches to developing a preventative HIV vaccine. Current Opinion in Investigational Drugs 2005, vol. 6, No. 2, p. 155-162. |
| Kusumi et al. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. Journal of Virology, Feb. 1992, vol. 66, No. 2, p. 875-885. |
| Meyerhans et al. Temporal fluctuations in HIV quasispeCies in vivo are not reflected by sequential HIV isolations. Cell 1989, vol. 58, p. 901-910. |
| Derosiers. Prospects for an AIDS vaccine. Nature Medicine Mar. 2004, vol. 10, No. 3, p. 221-223. |
| Leslie et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Medicine Mar. 2004 vol. 10, No. 3, pp. 282-289. |
| Altman et al. HIV escape: there and back again. Nature Medicine Mar. 2004 vol. 10, No. 3, p. 229-230. |
| Friedrich et al. Reversion of CTL escape—variant immunodeficiency viruses in vivo. Nature Medicine Mar. 2004 vol. 10, No. 3, p. 275-281. |
| Gallo. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 2005, vol. 366, p. 1897-1898. |
| Haigwood, Predictive Value of Primate Models for AIDS. AIDS Reviews 2004, vol. 6, p. 187-198. |
| Puls et al. Therapeutic vaccination against HIV: current progress and future possibilities. Clinical Science 2006, vol. 110, p. 59-71. |
| Von Laer et al. Gene therapy for HIV infection: what does it need to make it work? The Journal of Gene Medicine 2006, vol. 8, p. 658-667. |
| Mizrahi et al. Mutagenesis of the Conserved Aspartic Acid4 43, Glutamic Acid 478, Asparagine 494, and Aspartic Acid 498 Residues in the Ribonuclease H Domain of p66/p51 Human Immunodeficiency Virus Type I Reverse Transcriptase. The Journal of Biological Chemistry, Jul. 1994, vol. 269, No. 30, pp. 19245-19249. |
| Ayyavoo et al. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. AIDS 2000, vol. 14, pp. 1-9. |
| Englund et al. Integration is Required for Productive Infection of Monocyte-Derived Macrophages by Human Immunodeficiency Virus Type 1. Journal of Virology, May 1995, vol. 69, No. 5, pp. 3216-3219. |
| Caselli et al. DNA Immunization with HIV-1 tat Mutated in the trans Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat. The Journal of Immunology, 1999, vol. 162, pp. 5631-5638. |
| Zhang et al. Nucleocapsid Protein Effects on the Specificity of Retrovirus RNA Encapsidation. Journal of Virology, Sep. 1995, vol. 69, No. 9, pp. 5716-5722. |
| Le Grice et al. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. The EMBO Journal 1988, vol. 7, No. 8, pp. 2547-2553. |
| Wakefield et al. In Vitro Enzymatic Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants in the Highly Conserved YMDD Amino Acid Motif Correlates with the Infectious Potential of the Proviral Genome. Journal of Virology, Nov. 1992, vol. 66, No. 11, p. 6806-6812. |
| Sonnen et al. Characterization of pGA1, a new plasmid from Corynebacterium glutamicum LP-6. Gene 1991, vol. 107, p. 69-74. |
| Rodenburg et al. Near Full-Length Clones and Reference Sequences for Subtype C Isolates of HIV Type 1 from Three Different Continents. AIDS Research and Human Retroviruses, Jan. 2001, vol. 17, No. 2, pp. 161-168. |
| Allen et al., “Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen,” J. Immunol., 164: 4968-4978, 2000. |
| Amara et al., “Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine,” Science, 292: 69-74, 2001. |
| Andre et al., “Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage,” J. Virol., 72: 1497-1503, 1998. |
| Antoine et al., “The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses”, Virology, 244: 365-96, 1998. |
| Asakura et al., “Induction of HIV-1 specific mucosal immune responses by DNA vaccination,” Scand. J. Immunol., 46: 326-330, 1997. |
| Bachmann and Zinkernagel, “Neutralizing antiviral B cell responses,” in Ann. Rev. Immunol., 15: 235-270, 1997. |
| Barouch et al., “Reduction of Simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination,” J. Virol., 75: 5151-5158, 2001. |
| Barouch et al., “Control of Viremia and prevention of clinical AIDS in rhesis monkeys by cytokine-augmented DNA vaccination,” Science, 290: 486-492, 2000. |
| Barouch et al., “Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA caccines by IL-2/IG plasmid administration in rhesus monkeys”, Proc. Natl. Acad. Sci. U.S.A., 97:4192-7, Apr. 11, 2000. |
| Barry et al., “Protection against mycoplasma infection using expression-library immunization,” Nature, 377: 632-635, 1995. |
| Berger, “HIV Entry and Tropism: the chemokine receptor connection,” AIDS, 11(Suppl. A): S3-16, 1997. |
| Benson et al., J. Virol., “Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure,” 72: 4170-4182, 1998. |
| Blanchard et al., “Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine,” J. Gen. Virol., 79: 1159-1167, 1998. |
| Bohm et al., “DNA vector constructs that prime hepatitis B surface antigen-specific cytotoxic T lymphocyte and antibody responses in mice after intramuscular injection,” J. Immuno. Methods, 193: 29-40, 1996. |
| Bohm et al., “Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses,” Vaccine, 16: 949-54, 1998. |
| Bolivar et al., “Construction and Characterization of New Cloning Vehicles: (II. A Multipurpose Cloning System),” Gene, 2: 95-113, 1977. |
| Boyer et al., “Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination,” Nature Med., 3: 526-532, 1997. |
| Boyle et al., “Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization,” Int. Immunol., 9: 1897-1906, 1997. |
| Boyle et al., “Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction,” Nature, 392: 408-411, 1998. |
| Burton and Montefiori, “The antibody response in HIV-1 infection,” AIDS, 11(Suppl a):S87-98, 1997. |
| Calarota et al., “Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients,” Lancet, 351: 1320-1325, 1998. |
| Cardoso et al., “Immunization with Plasmid DNA Encoding for the Measles Virus Hemagglutinin and Nucleoprotein Leads to Humoral and Cell-Mediated Immunity,” Virology, 225: 293-299, 1998. |
| Carroll and Moss, “Host Range, and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccina Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line”, Virology, 238:198-211, 1997. |
| Chapman et al., “Effect of intron a from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells,” Nucl. Acids Res., 19: 3979-3986, 1991. |
| Chen et al., “Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles,” J. Virol., 72: 5757-5761, 1998. |
| Chun et al., “Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection,” Proc. Natl. Acad. USA, 95: 8869-8873, 1998. |
| Collman et al., “An Infection Molecular Clone of an Unusual Microphage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1,” J. Virol., 66: 7517-7521, 1992. |
| Condon et al., “DNA-based immunization by in vivo transfection of dendritic cells,” Nat Med., 2:1122-1128, 1996. |
| Corr et al., “Gene Vaccination with Naked Plasmid DNA: Mechanism of CTL Priming,” J. Exp. Med., 184: 1555-1560, 1996. |
| Dempsey et al., C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity, Science, 271: 348-350, 1996. |
| Durbin et al., “Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies,” J. Infect. Dis., 179: 1345-1351, 1999. |
| Durbin et al., “The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys”, Vaccine, 16: 1324-30, 1998. |
| Egan et al., “Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection,” J Virol., 74:7485-7495, 2000. |
| Endo et al., “Short- and Long-term Clinical Outcomes in Rhesus Monkeys Inoculated with a Highly Pathogenic Chimeric Simian/Human Immunodeficiency Virus”, J. Virol., 74:6935-45, 2000. |
| Esparza and Bhamarapravati, “Accelerating the development and future availability of JIV-1 vaccines: why, when, where, and how?”, Lancet, 355: 2061-6, 2000. |
| Evans DT et al., “Virus-specific T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef,” Nat. Med., 5: 1270-1276, 1999. |
| Feltquate et al., “Different T Helper Cell Types and Antibody Isotypes Generated by Saline and Gene Gun DNA Immunization,” J. Immunol. 158: 2278-2284, 1997. |
| Finzi et al., “Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy”, Nat. Med. 5: 1270-6, 1996. |
| Fomsgaard et al., “Improved Humoral and Cellular Immune Responses Against the gp120 V3 Loop of HIV-1 Following Genetic Immunization with a Chimeric DNA Vaccine Encoding the V3 Inserted into the Hepatitis B Surface Antigen,” Scand. J. Immunol., 47: 289-295, 1998. |
| Fu et al., “Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes,” Mol. Med., 3: 362-371, 1997. |
| Furci et al., “Antigen-driven C-C Chemokine-mediated HIV-1 Suppression by CD4 T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele”, J. Exp. Med., 186:455-60, 1997. |
| Fynan et al., “DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations,” Proc. Natl. Acad. Sci. USA, 90: 11478-11482, 1993. |
| Gorelick et al., “Nucleocapsid Protein Zinc-Finger Mutants of Simian Immunodeficiency Virus Strain Mne Produce Virions That are Replication Defective in Vitro and in Vivo”, Virology, 259-70, 1999. |
| Goulder et al., “Anti-HIV cellular immunity: recent advances towards vaccine design”, AIDS, 13: S121-36, 1999. |
| Hakim et al., “A Nine-Amino Acid Peptide from IL-1β Augments Antitumor Immune Responses Induced by Protein and DNA Vaccines,” J. Immunol., 157: 5503-5511, 1996. |
| Hanke, “Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen,” J. Virol., 73: 7524-7532, 1999. |
| Hanke et al., “Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime,” Vaccine, 16: 439-445, 1998a. |
| Hanke et al., “DNA multi-CTL epitope vaccines for HIV and Plasmodium faciparum: immunogenicity in mice,” Vaccine, 16: 426-435, 1998b. |
| Hartikka et al., “An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal MusCle,” Hum. Gen. Therapy, 7: 1205-1217, 1996. |
| Hirsch et al., “Prolonged Clinical Latency and Survival of Macaques Given a Whole Inactivated Simian Immunodeficiency Virus Vaccine”, J. Infect. Dis., 170:51-9, 1994. |
| Hofmann-Lehmann et al., “Sensitive and robust one-tube real-time reverse Transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one-versus two-enzyme systems,” AIDS Res. Hum. Retroviruses, 16: 1247-1257, 2000. |
| Inchauspe et al., “Plasmid DNA Expressing a Secreted or a Nonsecreted Form of Hepatitis C Virus Nucleocapsid: Comparative Studies of Antibody and T-Helper Responses Following Genetic Immunization,” DNA Cell Biol., 16: 185-195, 1997. |
| Iwasaki et al., “Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines,” J. Immunol., 158: 4591-4601, 1997a. |
| Iwasaki et al., “The dominant role of bone-marrow derived cells in CTL induction following plasmid DNA immunization at different sites,” J. Immunol., 159: 11-14, 1997b. |
| Jin et al., “Dramatic Rise in Plasma Viremia after CD8 T Cell Depletion in Simian Immunodeficiency Virus-infected Macaques”, J. Exp. Med., 189: 991-8, 1999. |
| Jones et al., “Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration,” Vaccine, 15: 814-817, 1997. |
| Knapp et al., “A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing,” Tissue Antigens, 50: 657-661, 1997. |
| Korber et al., “Epidemiological and Immunological Implications of the Global Variability of HIV” Retroviral Immunology, B. Walker, D. Pantaleo, Eds (The Humana Press, Totowa, NH, in press). |
| Lechner et at., “Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus”, J. Exp. Med., 191:1499-1512, 2000. |
| Letvin et al., “Cytotoxic T lymphocytes specific for the simian immunodeficiency virus”, lmmunol. Rev., 170: 127-34, 1999. |
| Letvin et at., “Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination,” Proc. Natl. Acad. Sci. USA, 94: 9378-9383, 1997. |
| Li et al., “Infection of Cynomolgus Monkeys with a Chimeric HIV-2/SIVmac Virus That Expresses the HIV-1 Envelope Glycoproteins,” J. of AIDS, 5: 639-646, 1992. |
| Lifson et al., “The Extent of Early Viral Replication is a Critical Determinant of the Natural History of Simian Immunodeficiency Virus Infection”, J. Virol., 71: 9508-14, 1997. |
| Livingston et al., “The Induction of Mucosal Immunity in the Female Genital Tract Using Gene-Gun Technology (Part 1: Antigen Expression),” Ann. New York Acad. Sci., 772: 265-267, 1995. |
| Lu et al., “SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups,” Vaccine 15: 920-923, 1997. |
| Maecker et al., “DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin,” Vaccine, 15: 1687-1696, 1997. |
| Maecker et al., “Cytotoxic T Cell Responses to DNA Vaccination: Dependence on Antigen Presentation via Class II MHC1,” J. Immunol., 161: 6532-6536, 1998. |
| Mahnel et al., “[Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA],” Berl. Munch Tierarztl Wochenschr, 107: 253-256, 1994. [English Translation of Abstract Attached]. |
| Manthorpe et al., “Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice,” Hum. Gene Therapy, 4: 419-431, 1993. |
| Mayr et al., “[The smallpox vaccination strain MVA: marker, genetic structure,.experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's trans1)],” Zentralbl. Bakteriol., 167: 375-390, 1978. [English Translation of Abstract Attached]. |
| McCluskie et al., “Direct Gene Transfer to the Respiratory Tract of Mice with Pure Plasmid and Lipid-Formulated DNA”, Antisense Nucleic Acid Drug Dev., 8: 401-414, 1998. |
| Mellors et al., “Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma” Science, 272:1167-70, 1996. |
| Montefiori et al., “Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1,” J. Virol., 72: 3427-3431, 1998. |
| Montefiori et al., “Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay,” J. Clin. Microbiol., 26: 231-237, 1988. |
| Montgomery et al., “Heterologous and Homologous Protection Against Influenza a by DNA Vaccination: Optimization of DNA Vectors,” DNA Cell Biol., 12: 777-783, 1993. |
| Moore et al., “HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells,” AIDS, 9(Suppl. A):S117-136, 1995. |
| Murali-Krishna et al., “Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection,” Immunity, 8:177-187, 1998. |
| Murali-Krishna et al., “Persistence of Memory CD8T Cells in MHC Class 1-Deficient Mice”, Science, 286:1377-81, 1999. |
| Ourmanov et al., “Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV,” J. Virol., 74: 2740-2751, 2000. |
| Ourmanov et al., “Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques,” J. Virol., 74: 2960-2965, 2000. |
| Pertmer and Robinson, “Studies on Antibody Responses Following Neonatal Immunization with Influenza Hemagglutinin DNA or Protein,” Virology, 257:406-414, (1999). |
| Pertmer et al., “Influenza Virus Nucleoprotein-Specific Immunoglobin G Subclass and Cytokine Responses Elicited by DNA Vaccination Are Dependent on the Route of Vector DNA Delivery,” J. Virol., 70: 6119-6125, 1996. |
| Pertmer et al., “Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA,” Vaccine, 13: 1427-1430, 1995. |
| Poignard et al., “Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection in Vivo,” Immunity, 10: 431-438, 1999. |
| Power et al., “A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells,” J. Immunol. Methods, 227: 99-107, 1999. |
| Reimann et al., “A Chimeric Simian/Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate env Causes an AIDS-Like Disease after in Vivo Passage in Rhesus Monkeys,” J. Virol., 70: 6922-6928, 1996. |
| Robinson and Pertmer, “DNA Vaccines: Basic Studies and Res., 55: 1-74, 2000. Applications,” in Adv. Virus Res., 55: 1-74, 2000. |
| Robinson et al., “AIDS Vaccines: Heterologous Prime/Boost Strategies for raising . Protective T Cell Responses”, AIDS Reviews, 2:105-110, 2000. |
| Robinson and Pertmer, Nucleic Acid Immunology, in Current Protocols in Ummunology, (R. Coico, Ed.), vol. 1, pp. 2.14.1-2.14.19.3 vols. John Wiley & Sons, Inc., New York. |
| Robinson et al., “The Scientific Future of DNA for Immunization,” American Academy of Microbiology, May 13-Jun. 2, 1996, 1997. |
| Robinson et al., “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations,” Nature Med., 5: 526, 1999. |
| Rodriguez et al., “DNA Immunization: Ubiquitination of a Viral Protein Enhances.Cytotoxic T-Lymphocyte Induction and Antiviral Protection but Abrogates Antibody Induction,” J. Virol., 71: 8497-8503, 1997. |
| Ross et al., “C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge,” Nat. Immunology, 1:127-131, 2000. |
| Ross et al., “Enhanced Avidity Maturation of Antibody to Human Immunodeficiency Virus Envelope: DNA Vaccination with gp120-C3d Fusion Proteins,” AIDS Res. Human Retro., 17(a):829-835, 2001. |
| Rubbert et al., “Multifactorial nature of non cytolytic CD8+ T cell-mediated suppression of HIV replication: beta-chemokine dependent and independent effects,” AIDS Res. Hum. Retroviruses 13: 63-9, 1997. |
| Sasaki et al., “Comparison of Intranasal and Intramuscular Immunization against Human Immunodeficiency Virus Type 1 with a DNA-Monophosphoryl Lipid A Adjuvant Vaccine,” Infect. Immunol., 66: 823-826, 1998. |
| Sauter et al., “An Internalization Signal in the Simian Immunodeficiency Virus Transmembrane Protein Cytoplasmic Domain Modulates Expression of Envelope Glycoproteins on the Cell Surface”, J. Cell Biol., 132: 795-811, 1996. |
| Schmitz et al., “Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 Lymphocytes”, Science, 283: 857-60, 1999. |
| Schneider et al., “Induction of CD8 cells using heterologous prime-boost immunisation strategies”, Immunol. Rev., 170: 29-38, 1999. |
| Schneider et al., “Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara,” Nat. Med., 4: 397-402, 1998. |
| Scholtissek et al., “A cloning cartridge of λto terminator,” Nucleic Acids Res., 15: 3185, 1987. |
| Sizemore et al., “Attentuated shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization,” Science, 270: 299-302, 1995. |
| Sizemore et al., “Attentuated bacteria as a DNA delivery vehicle for DNA-mediated immunization,” Vaccine, 15: 804-807, 1997. |
| Staprans et al., “Simian Immunodeficiency Virus Disease Course is Predicted by the Extent of Virus replication during Primary Infection”, J. Virol., 73:4829-39, 1999. |
| Staprans et al., “Quantitative Methods to Monitor Viral Load in Simian Infections,” in Viral Genome Methods, K. Adolph, Ed., CRC Press, Boca Raton, FL, pp. 167-184, 1996). |
| Stittelaar et al., “Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies,” J. Virol., 74: 4236-4243, 2000. |
| Subbarao et al., “Genetic variability of HIV1,” AIDS, 10(Suppl. A):S13-23, 1996. |
| Sutcliffe, “Complete nucleotide sequence of the Escherichia coli plasmid pBR322,” Cold Spring Harbor Quant. Biol., 43: 77-90, 1979. |
| Sutter et al., “Nonreplicating vaccinia vector efficiently expresses recombinant genes,” Proc. Natl. Acad. Sci. USA, 89: 10847-10851, 1992. |
| Tang et al., “Genetic immunization is a simple method for eliciting an immune response,” Nature, 356: 152-154, 1992. |
| Thomson et al., “Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination,” J. Immunol., 160: 1717-1723, 1998. |
| Tobery et al., “Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses in Vivo After Immunization,” J. Exp. Med., 185: 909-920, 1997. |
| Tomaras et al., “CD8 T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression”, Proc. Natl. Acad. Sci. U.S.A, 97:3503-8, 2000. |
| Torres et al., “DNA immunization: effect of secretion of DNA-expressed hemaggutinins on antibody responses,” Vaccine, 18: 805-814, 2000. |
| Torres et al., “Differential Dependence on Target Site Tissue for Gene Gun and Intramuscular DNA Immunizations,” J. Immunol., 158: 4529-4532, 1997. |
| Uchijima et al., “Optimization of Codon Usage of Plasmid DNA Vaccine is Required for the Effective MHC Class I-Restricted T Cell Responses Against an Intracellular Bacterium,” J. Immunol., 161: 5594-5599, 1998. |
| Ulmer et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,” Science 259: 1745-1749, 1993. |
| Villinger et al., “Induction of Long-Term Protective Effects against Heterologous Challenge in SIVhu-Infected Macaques”, Virology, 278:194-206, 2000. |
| Waldrop et al., “Determination of Antigen-specific Memory/Effector CD4 T Cell Frequencies by Flow Cytometry”, J. Clin. Invest., 99:1739-50, 1997. |
| Watson et al., “Plasma Viremia in Macaques Infected with Simian Immunodeficiency Virus: Plasma Viral Load Early in Infection Predicts Survival”, J. Virol., 71: 284-90, 1997. |
| Wild et al., “Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid,” Vaccine, 16: 353-360, 1998. |
| Wolff et al. “Direct Gene Transfer into Mouse Muscle in Vivo,” Science, 247: 1465-1468, 1990. |
| Wu et al., “Deoxyribonucleic Acid Vaccines Encoding Antigens With Rapid Proteasome-Dependent Degradation Are Highly Efficient Inducers of Cytolytic T Lymphocytes,” J. Immunol., 159: 6037-6043, 1997. |
| Wyand et al., “Protection by live, attenuated simian immunodeficiency virus against heterologous challenge,” J. Virol., 73: 8356-8363, 1999. |
| Wyatt et al., “Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara,” Virology, 251:334-42, 1998. |
| Xiang et al., “Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines,” Immunity, 2: 129-135, 1995. |
| Yamamoto et al., “Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems,” J. Virol. Methods, 61: 135-143, 1996. |
| Yang and Walker, “CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication,” Adv. Immunol., 66: 273-311, 1997. |
| Zajac et al., “Viral Immune Evasion Due to Presistence of Activated T Cells Without Effector Function”, J. Exp. Med., 188:2205-13, 1998. |
| Amara et al., “Different patterns of immune responses but similar control of a simianhuman immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines,” J. Virol., 76:7625-31, 2002. |
| Jacobsen et al., “Characterization of Human Immunodeficiency Virus Type I Mutants with Decreased Sensitivity to Proteinase Inhibitor Ro 31/8959,” Virology, 206:527-534, 1995. |
| Meyer et al., “Search for a putative scrapie genome in purified prion fractions reveals a paucity of nucleic acids,” J. Gen. Virol., 72:1031-1038, 1991. |
| Smith et al., “Recombinant vaccinia viruses as new live vaccines,” Biotechnol Genet Eng Rev., 2:383-407, 1984. |
| Amara et al., “Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines,” J. Virology 76:7625-7631 (2002). |
| Jacobsen et al., “Characterization of Human Immunodeficiency Virus Type 1 Mutants with Decreased Sensitivity to Proteinase Inhibitor Ro 31-8959,” J. Virology 206:527-534 (1995). |
| Meyer et al., “Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence,” J. Gen. Virology 72:1031-1038 (1991). |
| Smith et al., “Recombinant Vaccinia Viruses as New Live Vaccines,” Biotechnology & Genetic Engineering Reviews 2:383-407 (1984). |
| Huang et al., “Human Immunodeficiency Virus Type 1-Specific Immunity . . .” J. of Virology 75:4947-4951, 2001. |
| Kong et al., “Immunogenicity of Mutliple Gene and Clade Human Immunodeficiency..” J. of Virology 77(23):12764-12772, 2003. |
| Megede et al., “Increased Expression and Immunogenicity of Sequence-Modified . . .” J. of Virology 74(6):2628-2635, 2000. |
| Persson et al., “Modifications of HIV-1 Retrovirus-Like Particles to Enhance . . .” Biologicals 26:255-265, 1998. |
| Smith et al., “Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: . . .” AIDS Research and Human Retroviruses 20(6):654-665, 2004. |
| Accession No. AF430344; (XP-002321209); Smith et al., Oct. 9, 2001. |
| Accession No. AF426288; (XP-002321210); Smith et al., Mar. 12, 2002. |
| Burton et al., “Why do we not have an HIV vaccine and how can we make one?” Nature Med. 4:495-498, 1998. |
| Feinberg et al., “AIDS vaccine models” Challenging challenge viruses Nature Med. 8(3):207-210, 2002. |
| Letvin, N.L. “Progress in the development of an HIV-1 vaccine” Science 280:1875-1880, 1998. |
| Belyakov et al., “Induction of a Mucosal Cytotoxic T-Lymphocyte Response by . . .” J. of Virology 72(1):8264-8272, 1998. |
| .Davison et al., “Structure of Vaccinia Virus Early Promoters” J. Mol. Biol. 210:749-769, 1989. |
| Earl, P.L. et al., “Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model” Virology (2002) 294:270-281. |
| Girard, M. et al., “New prospects, for the development of a vaccine against human immunodeficiency virus type 1. An overview” C.R. Acad. Sci. Paris, Sciences de la Vie/Life Sciences (1999) 322:959-966. |
| Gomez, C.E. et alk, 2001 “Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments” Arch Virol. 146(5):875-892. |
| Haffar et al., “The Carboxy Terminus of Human Immunodeficiency Virus Type I gp 160 . . .” J. of Virology 64(6):3100-3103, 1990. |
| Hanke et al., “Development of a DNA-MVA/HIVA vaccine for Kenya” Vaccine 20:1995-1998, 2002. |
| Hanke et al., “Effective induction of HIV-specific CTL by multi-epitope using gene gun . . .” Vaccine 17:589-596, 1999. |
| Hanke et al., “Immunogenicities of intravenous and intramuscular administrations of modified vaccinia . . .” J. of General Virology 79:83-90, 1998. |
| Hanke et al., “Lack of toxicity and persistence in the mouse associated with administration of candidate . . .” Vaccine 21:108-114, 2002. |
| Hanke et al., “Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for ADS” Immunology Letters 66:177-181, 1999. |
| Hirsch, V.M. et al., 1995 “Limited virus replication following SIV challenge of macaques immunized with attenuated MVA vaccinia expressing SIV sm envand gag-pol” Vaccines 95:195-200. |
| Karacostas, V. et al., 1989 “Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector” PNAS USA 86:8964-8967. |
| Masternak et al., “cis- and trans-Acting Elements Involved in Reactivation of Vaccinia Virus Early Transcription” J. of Virology 70(12):8737-8746, 1996. |
| Men, R. et al., “Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge” Vaccine (2000) 18:3113-3122. |
| Moss, B. et al., 2000 “Retroviruses of human AIDS and related animal diseases” in: Colloque des Cent Gardes, 12th, Paris, France, Oct. 25-27, 1999, Meeting Date 1999, 105-107, Eds. M. Girard & B. Dodet, Editions Scientifiques et Medicales Elsevier, Paris, Fr. (Abstract). |
| Wee et al., “A DNA/MVA-based candidate human immunodeficiency virus for Kenya induces . . .” J. of General Virology 83:75-80, 2002. |
| Wyatt et al., “Development of a replication-deficient recombinant vaccinia virus vaccine effective against . . .” Vaccine 14(15):1451-1458, 1996. |
| Wyatt et al., “Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective . . .” Vaccine 18:392-397, 2000. |
| Andersson et al., “Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 . . .” J. of Biol. Chem. vol. 264 (1441222-8229, 1989. |
| Markmeyer et al., “The pAX plasmids: new gene-fusion vectors for sequencing, mutagenesis and expression of proteins in E.coli,” Gene 93:129-134 (1990). |
| Mizuno et al., “Mutational analysis of two zinc-finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation,” Aides Research and Human Retroviruses 12(9):793-800 (1996). |
| Wang et al., “Mammalian cell/vaccinia virus expression vectors with increased stability of retroviral sequences in E.coli; production of feline immunodeficiency virus envelope protein,” Gene 153:197-202 (1995). |
| U.S. Appl. No. 09/798,675, mail date Jul. 1, 2002, Restriction Requirement. |
| U.S. Appl. No. 09/798,675, mail date Feb. 27, 2003, Non-Final Office Action. |
| U.S. Appl. No. 09/798,675, mail date Dec. 5, 2003, Final Office Action. |
| U.S. Appl. No. 09/798,675, mail date Jun. 9, 2004, Non-Final Office Action. |
| U.S. Appl. No. 10/093,953, mail date Jul. 15, 2005, Non-Final Office Action. |
| U.S. Appl. No. 11/009,063, mail date Apr. 13, 2007, Non-Final Office Action. |
| U.S. Appl. No. 11/333,770, mail date Mar. 21, 2007, Restriction Requirement. |
| U.S. Appl. No. 10/646,628, mail Dec. 12, 2004, Restriction Requirement. |
| U.S. Appl. No. 10/646,628, mail date Sep. 20, 2005, Non-Final Office Action. |
| U.S. Appl. No. 10/646,628, mail date Sep. 13, 2006, Final Office Action. |
| U.S. Appl. No. 10/646,628, mail date Jul. 19, 2007, Non-Final Office Action. |
| U.S. Appl. No. 11/764,766, filed Jun. 18, 2007. |
| U.S. Appl. No. 12/033,300, filed Feb. 19, 2008. |
| U.S. Appl. No. 12/018,150, filed Jan. 22, 2008. |
| U.S. Appl. No. 11/574,285, filed Feb. 26, 2007. |
| Sipsas et al., “Identification of Type-specific Cytotoxic Y Lymphocyte Responses . . .” J. Clin. Invest. vol. 99(4):752-762, 1997. |
| Chen W-J et al., “cDNA cloning and expression of the peptide-binding beta subunit of rat p21<ras>farnesyltransferase, the counterpart of yeast DPR1/RAM1,” Cell 66:327-334 (1991). |
| Gendler S J et al., “Molecular Cloning and Expression of Human Tumor-Associated Polymorphic Epithelial Mucin,” Journal of Biological Chemistry 265:15286-15293 (1990). |
| Karlsson et al., “Characterization of Molecularly Cloned Simian-Human Immunodeficiency Viruses Causing Rapid CD4 Lymphocyte Depletion in Rhesus Monkeys”, J. Virol., 71: 4218-25, 1997. |
| Kawabata et al., “The Fate of Plasmid DNA After Intravenous Injection in Mice: Involvement of Scavenger Receptors in Its Hepatic Uptake,” Pharm. Res., 12: 825-830, 1995. |
| Kent et al., “Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Recombinant Fowlpox Virus,” J. Virol., 72: 10180-10188, 1998. |
| Kern et al., “Target Structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited,” J. Virol., 73: 8179-8184, 1999. |
| Knapp et al., “A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing,” Tissue Antigens, 50:657-661, 1997. |
| Korber et al., “Epidemiological and Immunological Implications of the Global Variability of HIV” Retroviral Immunology , B. Walker, D. Pantaleo, Eds (The Humana Press, Totowa, NH, In press), pp. 1-32, 2001. |
| Kuroda et al., “Analysis of Gag-specific Cytotoxic T Lymphocytes in Simian Immunodeficiency Virus-infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I-Peptide Complex,” J. Exp. Med., 187: 1373-1381, 1998. |
| Lau et al., “Cytotoxic T-cell memory without antigen”, Nature, 369: 648-52, 1994. |
| Lechner et al., “Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus”, J. Exp. Med., 191: 1499-1512, 2000. |
| Letvin et al., “Cytotoxic T lymphocytes specific for the simian immunodeficiency virus”, Immunol. Rev., 170: 127-34, 1999. |
| Letvin et al., “Potent protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination,” Proc. Natl. Acad. Sci. USA, 94: 9378-9383, 1997. |
| Levy et al., “Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8 T cells”, Immunol. Today, 17: 217-24, 1996. |
| Lew et al., “Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetic Study of DNA Following Injection in Mice,” Hum. Gene Ther., 6: 553, 1995. |
| Lewis, et al., “Limited Protection from a Pathogenic Chimeric Simian-Human Immunodeficiency Virus Challenge following Immunization with Attenuated Simian Immunodeficiency Virus”, J. Virol., 73: 1262-70, 1999. |
| Li et al., “Infection of Cynomolgus Monkeys with a Chimeric HIV-2/SIVmac Virus That Expresses the HIV-1 Envelope Glycoproteins,” J. of AIDS, 5: 639-646, 1992. |
| Lifson et al., “The Extent of Early Viral Replication Is a Critical Determinant of the Nature History of Simian Immunodeficiency Virus Infection”, J. Virol., 71: 9508-14, 1997. |
| Ourmanov et al., “Recombinant modified vaccinia virus ankara expressing the surface gpI20 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques,” J. Virol., 74: 2960-2965, 2000. |
| Pal et al., “Inhibition of HIV-1 infection by the β-Chemokine MDC”, Science, 278: 695-8, 1997. |
| Pertmer and Robinson, “Studies on Antibody Responses Following Neonatal Immunization with Influenza Hemagglutinin DNA or Protein,” Virology, 257: 406-414, (1999). |
| Pertmer et al., “Influenza Virus Ncleoprotein-Specific Immunoglobin G Subclass and Cytokine Responses Elicited by DNA Vaccination are Dependant on the Route of Vector DNA Delivery,” J. Virol., 70: 6119-6125, 1996. |
| Pertmer et al., “Gene gun-based nucleis acid immunication: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA,” Vaccine, 13: 1427-1430, 1995. |
| Poignard et al., “Neutralizing Antibodies Have Limited Effects of the Control of Established HIV-1 Infection In Vivo,” Immunity, 10: 431-438, 1999. |
| Porgador et al., “Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization,” J. Exp. Med., 188: 1075-1082, 1998. |
| Power et al., “A valid ELISPOT essay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells,” J. Immunol. Methods, 227: 99-107, 1999. |
| Quinn et al., “Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1”, N. Eng. J. Med., 342: 921-9, 2000. |
| Ramshaw and Ramsey, “The prime-boost strategy: exciting prospects for improved vaccination”, Immunol. Today, 21: 163-5, 2000. |
| Reimann et al., “An env Gene Derived from a Primary Human Immunodeficiency Virus Type 1 Isolate Confers High In Vivo Replicative Capacity to a Chimeric Simian/Human Immunodeficiency Virus in Rhesus Monkeys,” J. Virol., 70: 3198-3206, 1996. |
| Reimann et al., “A Chimeric Simian/Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate env Causes as AIDS-Like Disease after In Vivo Passage in Rhesus Monkeys,” J. Virol., 70: 6922-6928, 1996. |
| Richmond et al., “Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting,” J. Virol., 72: 9092-9100, 1998. |
| Robinson and Pertmer, “DNA Vaccines: Basic Studies and Applications,” in Adv. Virus Res., 55: 1-74, 2000. |
| Robinson et al., “AIDS Vaccines: Heterologous Prime/Boost Strategies for raising Protective T Cell Reponses”, AIDS Reviews, 2: 105-110, 2000. |
| Robinson and Pertmer, “Nucleic Acid Immunizations,” in Current Protocols in Immunology , (R. Coico, Ed.), vol. 1, pp. 2.14.1-2.14.19.3 vols. John Wiley & Sons, Inc., New York, 2001. |
| Robinson et al., “Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA,” Vaccine, 11: 957-960, 1993. |
| Markrneyer et al., “The pAX plasmids: new gene-fusion vectors for sequencing, mutagenesis and expression of proteins in E.coli,” Gene 93: 129-134 (1990). |
| Mizuno et al., “Mutational analysis of two zinc-finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation,” Aides Research and Human Retroviruses 12(9): 793-800 (1996). |
| Wang et al., “Mammalian cell/vaccinia virus expression vectors with increased stability of retroviral sequences in E.coli; production of feline immunodeficiency virus envelope protein,” Gene 153: 197-202 (1995). |
| Number | Date | Country | |
|---|---|---|---|
| 20030175292 A1 | Sep 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60325004 | Sep 2001 | US | |
| 60324845 | Sep 2001 | US | |
| 60186364 | Mar 2000 | US | |
| 60251083 | Dec 2000 | US | |
| 60274434 | Mar 2001 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10093953 | Mar 2002 | US |
| Child | 10336566 | US | |
| Parent | 09798675 | Mar 2001 | US |
| Child | 10093953 | US | |
| Parent | PCT/US01/06795 | Mar 2001 | US |
| Child | 10093953 | US | |
| Parent | 10336566 | US | |
| Child | 10093953 | US | |
| Parent | PCT/US02/06713 | Mar 2002 | US |
| Child | 10336566 | US |
